var title_f12_61_13264="Passive extension of wrist";
var content_f12_61_13264=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F63786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F63786&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Passive extension of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 287px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pain with passive terminal wrist extension with the elbow in full extension is consistent with medial epicondylitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Neeru Jayanthi, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13264=[""].join("\n");
var outline_f12_61_13264=null;
var title_f12_61_13265="Antinuclear antibodies (ANA)";
var content_f12_61_13265=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/61/13265/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13265/contributors\" id=\"au8073\">",
"       Donald B Bloch, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/61/13265/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13265/contributors\" id=\"se5833\">",
"       Robert H Shmerling, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?12/61/13265/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13265/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?12/61/13265?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ANTINUCLEAR ANTIBODIES OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     A healthcare provider may request that a patient have a test for antinuclear antibodies (ANA) as part of an evaluation for possible autoimmune disease. Antibodies are proteins that are made as part of an immune response. Normally, the immune system responds to an infection by producing large numbers of antibodies to fight bacteria or viruses. However, when a person has an autoimmune disease, the immune system malfunctions and may produce large amounts of potentially harmful antibodies directed against one&rsquo;s own body. These self-directed antibodies are referred to as autoantibodies. Autoantibody-mediated inflammation and cell destruction may affect blood cells, skin, joints, kidneys, lungs, nervous system, and other organs of the body.",
"    </p>",
"    <p>",
"     The ANA test identifies autoantibodies that target substances contained inside cells. Although the name implies that the test detects only autoantibodies directed against components of the nucleus, the test can also be used to detect antibodies directed against cellular components that are contained within the cell cytoplasm, outside of the nucleus.",
"    </p>",
"    <p>",
"     Because symptoms of autoimmune disorders often vary from patient to patient, these diseases may be very difficult to diagnose. Together with a healthcare provider&rsquo;s careful consideration of a patient&rsquo;s symptoms, physical findings, and other laboratory test results, a positive ANA test may assist in the diagnosis of autoimmune diseases.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25516672\">",
"     <span class=\"h1\">",
"      INTERPRETING ANTINUCLEAR ANTIBODIES RESULTS",
"     </span>",
"    </p>",
"    <p>",
"     In the ANA test, antinuclear (or anti-cytoplasmic) antibodies bind to cells that have been fixed on a slide. The addition of a secondary antibody (with an attached fluorescent dye) directed against human antibodies may reveal staining of the nucleus or cytoplasm under a fluorescence microscope. Patient samples are often screened for ANA after being diluted 1:40 and 1:160 in a buffered solution. If staining is observed at both the 1:40 and 1:160 dilutions, then the laboratory continues to dilute the sample until staining can no longer be seen under the microscope. The level to which a patient&rsquo;s sample can be diluted, and still produce recognizable staining, is known as the ANA &ldquo;titer.&rdquo; The ANA titer is a measure of the amount of ANA in the blood; the higher the titer, the more autoantibodies are present in the sample.",
"    </p>",
"    <p>",
"     It is difficult to standardize the ANA test between laboratories. One approach has been to modify the test reagents such that 30 percent of normal individuals will have a positive test when their sample is tested at a dilution of 1:40. This standardization makes the ANA test very",
"     <strong>",
"      sensitive",
"     </strong>",
"     <em>",
"     </em>",
"     for the diagnosis of autoimmune diseases but results in many false positive results. At a dilution of 1:160, only 5 percent of normal individuals have a positive test for ANA. The 1:160 dilution increases the",
"     <strong>",
"      specificity",
"     </strong>",
"     of the ANA test for the diagnosis of autoimmune diseases.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ANTINUCLEAR ANTIBODIES TESTING",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A positive test for ANA may assist healthcare providers in establishing the diagnosis of an autoimmune disease and may help determine the specific type of autoimmune disease that is affecting a patient.",
"      </li>",
"      <li>",
"       A negative test for ANA may assist healthcare providers by decreasing the likelihood that a patient&rsquo;s symptoms are caused by an autoimmune disease.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      THE SIGNIFICANCE OF ANTINUCLEAR ANTIBODIES",
"     </span>",
"    </p>",
"    <p>",
"     Patients with the following systemic autoimmune diseases may have a positive test for ANA:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Systemic lupus erythematosus (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"        \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Scleroderma",
"      </li>",
"      <li>",
"       Sj&ouml;gren's syndrome (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"        \"Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Mixed connective tissue disease",
"      </li>",
"      <li>",
"       Drug-induced lupus",
"      </li>",
"      <li>",
"       <span class=\"nowrap\">",
"        Polymyositis/dermatomyositis",
"       </span>",
"       (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"        \"Patient information: Myositis (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Rheumatoid arthritis (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"        \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Pauciarticular juvenile chronic arthritis",
"      </li>",
"      <li>",
"       Polyarteritis nodosum",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Patients with organ-specific autoimmune diseases may also have a positive test for ANA. These diseases include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Thyroid diseases (Hashimoto&rsquo;s thyroiditis, Grave&rsquo;s disease)",
"      </li>",
"      <li>",
"       Gastrointestinal diseases (autoimmune hepatitis, primary biliary cirrhosis, inflammatory bowel disease)",
"      </li>",
"      <li>",
"       Pulmonary diseases (Idiopathic pulmonary fibrosis)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Patients with infectious diseases may also test positive for ANA. These diseases include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Viral infections (Hepatitis C, Parvovirus)",
"      </li>",
"      <li>",
"       Bacterial infections (Tuberculosis)",
"      </li>",
"      <li>",
"       Parasitic infections (Schistosomiasis)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Other associations with positive ANA tests have been noted, including:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Various forms of cancer (rarely)",
"      </li>",
"      <li>",
"       As a harbinger of the future development of autoimmune disease",
"      </li>",
"      <li>",
"       Various medications, without causing an autoimmune disease",
"      </li>",
"      <li>",
"       Having one or more relatives with an autoimmune disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Some individuals, even those without a relative with autoimmune disease, may have a positive test for ANA and yet never develop any autoimmune disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      TYPES OF ANTINUCLEAR ANTIBODIES",
"     </span>",
"    </p>",
"    <p>",
"     If a patient has a positive test for ANA, his or her healthcare provider, depending on the patient&rsquo;s symptoms or findings on physical examination, may order additional tests to identify specific types of autoantibodies. Some examples are provided below:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25516715\">",
"     <span class=\"h2\">",
"      Systemic lupus erythematosus (SLE)",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a diagnosis of SLE is suspected, then additional tests, looking for autoantibodies directed against double-stranded DNA, Sm antigens, and ribosomal P antigens may be ordered. Because these antibodies are relatively specific for SLE, the results may provide important clues to facilitate the diagnosis of SLE. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      \"Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25517001\">",
"     <span class=\"h2\">",
"      Sj&ouml;gren&rsquo;s syndrome",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a diagnosis of Sj&ouml;gren&rsquo;s syndrome is suspected, the healthcare provider may test for autoantibodies directed against antigens known as",
"     <span class=\"nowrap\">",
"      Ro/SSA",
"     </span>",
"     and",
"     <span class=\"nowrap\">",
"      La/SSB.",
"     </span>",
"     The presence of these autoantibodies provides support for the diagnosis of Sj&ouml;gren&rsquo;s syndrome, a disorder which involves autoimmune destruction of the glands that produce tears and saliva.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25517009\">",
"     <span class=\"h2\">",
"      Drug-induced SLE",
"     </span>",
"     &nbsp;&mdash;&nbsp;If a diagnosis of drug-induced SLE is suspected, then a test for antihistone antibodies may be ordered. Antihistone antibodies are nearly always present in patients with drug-induced SLE. If antihistone antibodies are not detected, then the likelihood of this diagnosis (drug-induced SLE) is greatly reduced.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25517016\">",
"     <span class=\"h1\">",
"      A WORD OF CAUTION",
"     </span>",
"    </p>",
"    <p>",
"     A positive test for ANA does not, by itself, indicate the presence of an autoimmune disease. As mentioned above, because of the design of the ANA test, many normal individuals will have a positive test at low titers. Even when detected at high titer, a positive ANA result, by itself (in the absence of symptoms or physical findings), does not indicate that a patient either has, or will develop, an autoimmune disease. Some ANA appear to be unrelated to the development of autoimmune disorders. Future studies may help identify these &ldquo;benign&rdquo; autoantibodies and may permit healthcare providers to provide reassurance to their patients.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864033562\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13342574\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     This topic currently has no corresponding Basic content.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13342582\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/35/29238?source=see_link\">",
"      Patient information: Systemic lupus erythematosus (SLE) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?26/11/26804?source=see_link\">",
"      Patient information: Myositis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/61/21463?source=see_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/22/44389?source=see_link\">",
"      Patient information: Vasculitis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/11/44212?source=see_link\">",
"      Patient information: Sj&ouml;gren&rsquo;s syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864033569\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=see_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/11/2234?source=see_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=see_link\">",
"      Miscellaneous antinuclear antibodies",
"     </a>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Arthritis Foundation",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Lupus Foundation of America, Inc",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.lupus.org/\">",
"        www.lupus.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"        www.niams.nih.gov",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/003535.htm\">",
"        www.nlm.nih.gov/medlineplus/ency/article/003535.htm",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?12/61/13265/abstract/1\">",
"      1",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?12/61/13265?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     Leisy PS. \"My ANA is positive ... What does that mean?\" Lupus News (a publication of the Lupus Foundation of America). www.lupus.org/webmodules/webarticlesnet/templates/new_empty.aspx?articleid=402&amp;zoneid=76 (Accessed on November 28, 2011).",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f12_61_13265=[""].join("\n");
var outline_f12_61_13265=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ANTINUCLEAR ANTIBODIES OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25516672\">",
"           INTERPRETING ANTINUCLEAR ANTIBODIES RESULTS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ANTINUCLEAR ANTIBODIES TESTING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           THE SIGNIFICANCE OF ANTINUCLEAR ANTIBODIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           TYPES OF ANTINUCLEAR ANTIBODIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25517016\">",
"           A WORD OF CAUTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13266="TEP hernia reduction";
var content_f12_61_13266=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    TEP hernia reduction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 559px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Jones, DB, Maithel, SK, Schneider, BE. Atlas of minimally invasive surgery. Cin&eacute;-Med, Woodbury, CT 2006. Copyright &copy; 2006 Cin&eacute;-Med, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13266=[""].join("\n");
var outline_f12_61_13266=null;
var title_f12_61_13267="Diameters of the fetal head at term";
var content_f12_61_13267=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Diameters of the fetal head at term",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Measurements from: Cunnigham FG, Leveno KJ, Bloom SL, et al (Eds). Williams Obstetrics, 23rd Edition. New York: McGraw-Hill, 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13267=[""].join("\n");
var outline_f12_61_13267=null;
var title_f12_61_13268="Mometasone (topical): Patient drug information";
var content_f12_61_13268=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mometasone (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=see_link\">",
"     see \"Mometasone (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/8/13444?source=see_link\">",
"     see \"Mometasone (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8775141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elocon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8775142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elocom&reg;;",
"     </li>",
"     <li>",
"      PMS-Mometasone;",
"     </li>",
"     <li>",
"      ratio-Mometasone;",
"     </li>",
"     <li>",
"      Taro-Mometasone",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin rashes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702547",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to mometasone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696925",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use to treat diaper rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696929",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use on the face, underarms, or groin unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024306\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024312\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12258 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13268=[""].join("\n");
var outline_f12_61_13268=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775141\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8775142\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024301\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024303\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024302\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024307\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024308\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024310\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024305\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024306\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024311\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024312\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?37/23/38261?source=related_link\">",
"      Mometasone (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/4/7236?source=related_link\">",
"      Mometasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/20/42307?source=related_link\">",
"      Mometasone (nasal): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/11/34998?source=related_link\">",
"      Mometasone (oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/6/28773?source=related_link\">",
"      Mometasone (oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?42/46/43748?source=related_link\">",
"      Mometasone (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/8/13444?source=related_link\">",
"      Mometasone (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13269="Gadoxetate: Drug information";
var content_f12_61_13269=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gadoxetate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/3/14388?source=see_link\">",
"    see \"Gadoxetate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7083943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6893002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eovist&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10053613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Primovist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7083948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent;",
"     </li>",
"     <li>",
"      Gadolinium-Containing Contrast Agent;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Ionic, Low Osmolality);",
"     </li>",
"     <li>",
"      Radiological/Contrast Media, Paramagnetic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7083979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Visualization of liver lesions:",
"     </b>",
"     I.V.: 0.025 mmol/kg (0.1 mL/kg)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7083980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F7083981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose adjustment is not recommended; however, use with caution. Risk for NSF development increases as renal function decreases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     End-stage renal disease: Imaging performance decreases due to elevated serum ferritin levels; if used, complete MR imaging within 60 minutes following administration and use both noncontrast and contrast-enhanced images to aid in diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hemodialysis: If administered to patients already receiving hemodialysis, consider prompt hemodialysis following exposure (eg, within 3 hours) (Kuo, 2007). Data has shown hemodialysis enhances gadolinium elimination with average gadolinium excretory rates of 78%, 96%, and 99% in the first, second, and third hemodialysis sessions, respectively (Kuo, 2007; Okada, 2001).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peritoneal dialysis: Likely to be less efficient at clearing gadolinium (Joffe, 1998; Kuo, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F7083982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustments necessary for hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Severe hepatic impairment (including patients with elevated bilirubin &gt;3 mg/dL): Imaging performance decreases; if used, complete imaging no later than 60 minutes after administration and use a paired noncontrast and contrast image for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7083988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as disodium [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eovist&reg;: 181.43 mg/mL (10 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7083946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7083983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer undiluted as rapid I.V. bolus injection at a rate of ~2 mL/second. Flush line with NS to ensure complete injection of medium. Imaging should be completed within 2 hours of injection; in patients with severe hepatic dysfunction or end-stage renal disease, imaging should be completed within 1 hour of injection.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F7083968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not mix with other medications.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7083949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance imaging (MRI) to detect and characterize lesions within focal liver disease",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F12933057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contrast medium for magnetic resonance angiography (MRA)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F7083944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eovist&reg; may be confused with Evista&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7083959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (1%), headache (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Feeling of warmth (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylactoid reactions, blood pressure increased, bundle branch block, hyperhidrosis, hypersensitivity, nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy (NSF/NFD), paresthesia, parosmia, rash, respiratory distress, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7083955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any gadolinium-based contrast agent",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7083956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity, including anaphylactic reactions (rare), may occur; appropriate equipment (eg, ventilator) and emergency medications (eg, epinephrine) should be available during use. Delayed reactions may also occur (within hours to days). Patients with a history of allergic reactions and/or bronchial asthma may be at an increased risk for developing hypersensitivity reactions; use caution in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nephrogenic systemic fibrosis:",
"     <b>",
"      [U.S. Boxed Warning]: Gadolinium-based contrast agents (GBCAs) exposure may increase the risk for nephrogenic systemic fibrosis (NSF) in patients with renal impairment; avoid use unless GBCA enhanced imaging is essential for diagnostic purposes. The risk is highest in patients with acute kidney injury or chronic, severe renal disease (GFR &lt;30 mL/minute/1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      ).",
"     </b>",
"     The risk appears lower in patients with moderate, chronic renal disease (GFR 30-59 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ) and little, if any, in patients with mild, chronic renal disease (GFR 60-89 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     ). NSF, a potentially fatal disease, affects the skin, muscle, and internal organs and can occur days to months after exposure. All patients should be screened for renal dysfunction prior to administration; estimate GFR in patients at risk for chronic renal disease (diabetes, hypertension, age &gt;60 years). In patients at risk of NSF, do not exceed the recommended dosage and allow sufficient time (ie, several half-lives) for elimination prior to readministration (avoidance of readministration is preferred). In patients receiving hemodialysis, consider prompt initiation of hemodialysis following administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Severe hepatic failure, such as markedly elevated serum bilirubin (&gt;3 mg/dL),  may impair imaging performance; if used, complete MR imaging within 60 minutes following administration and use both noncontrast and contrast-enhanced images to aid in diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dose-dependent worsening of renal function or acute renal failure has occurred in patients with renal insufficiency following use of other gadolinium agents, generally within 48 hours following administration. Evaluate renal function in patients with renal impairment prior to use; consider follow-up monitoring. End-stage renal disease may impair imaging performance due to elevated serum ferritin levels; if used, complete MR imaging within 60 minutes following administration and use both noncontrast and contrast-enhanced images to aid in diagnosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell anemia: In",
"     <i>",
"      in vitro",
"     </i>",
"     studies, deoxygenated sickle erythrocytes align perpendicular to a magnetic field; the enhancement of magnetic moment by contrast agents may potentiate this alignment possibly resulting in vaso-occlusive complications",
"     <i>",
"      in vivo",
"     </i>",
"     . Use in patients with sickle cell anemia or other hemoglobinopathies has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Lesions with minimal or no hepatocyte function (eg, cysts, metastases, certain hepatocellular carcinomas) will generally not accumulate gadoxetate resulting in decreased visualization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation: Avoid extravasation; local tissue damage/reactions may occur. Ensure catheter patency prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7273313\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7083950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7083951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Gadolinium-based contrast agents cross the placenta in humans. Gadolinium-based agents should not routinely be administered to pregnant women (Expert Panel on MR Safety, 2013; Wang, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7083953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7083954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadolinium-based contrast agents are excreted in breast milk in small amounts and oral absorption is poor; information specific to gadoxetate  is not available. Although some sources state breast-feeding may be continued, the manufacturer recommends temporarily discontinuing breast-feeding following administration; breast--feeding may be resumed &ge;10 hours following administration of gadoxetate in women with normal renal function. Contrast media may temporarily alter the taste of breast milk (Tremblay, 2012; Webb, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Eovist Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25 mol/L (10 mL): $156.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7083986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs of hypersensitivity (during and for several hours after procedure); renal function (prior to administration); short- and long-term monitoring of signs and symptoms of NSF (eg, burning, itching, swelling, hardening and/or tightening of skin, joint stiffness, deep hip or rib bone pain, muscle weakness, limited range of motion, and/or yellowed/raised spots on whites of eye)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Primovist (AT, AU, BG, CH, CL, CZ, DE, EE, FI, GR, HN, IE, IT, NL, NO, PT, RU, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7083969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gadoxetate is a gadolinium-containing paramagnetic agent. Exposure to an external magnetic field induces a large local magnetic field in exposed tissues. This local magnetism disrupts water protons in the vicinity, resulting in a change in proton density and spin characteristics, which can be detected by the imaging device.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7083971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.21 L/kg; initial distribution in extracellular space, followed by selective uptake by hepatocytes; does not cross intact blood-brain barrier",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &lt;10%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Healthy volunteers: 0.91-0.95 hours; prolonged with hepatic or renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine; feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Nephrogenic Fibrosing Dermopathy Associated With Exposure to Gadolinium-Containing Contrast Agents -- St. Louis, Missouri, 2002-2006,&rdquo;",
"      <i>",
"       MMWR Weekly Rep",
"      </i>",
"      , 2007, 56(7):137-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/17318112/pubmed\" id=\"17318112\" target=\"_blank\">",
"        17318112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel on MR Safety, \"ACR Guidance Document on MR Safe Practices: 2013,\"",
"      <i>",
"       J Magn Reson Imaging",
"      </i>",
"      , 2013, 37(3):501-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/23345200/pubmed\" id=\"23345200\" target=\"_blank\">",
"        23345200",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joffe P, Thomsen HS, and Meusel M, \"Pharmacokinetics of Gadodiamide Injection in Patients with Severe Renal Insufficiency and Patients Undergoing Hemodialysis or Continuous Ambulatory Peritoneal Dialysis,\"",
"      <i>",
"       Acad Radiol",
"      </i>",
"      , 1998, 5(7):491-502.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/9653466/pubmed\" id=\"9653466\" target=\"_blank\">",
"        9653466",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kuo PH, Kanal E, Abu-Alfa AK, et al, \"Gadolinium-Based MR Contrast Agents and Nephrogenic Systemic Fibrosis,\"",
"      <i>",
"       Radiology",
"      </i>",
"      , 2007, 242(3):647-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/17213364/pubmed\" id=\"17213364\" target=\"_blank\">",
"        17213364",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Okada S, Katagiri K, Kumazaki T, et al, &ldquo;Safety of Gadolinium Contrast Agent in Hemodialysis Patients,&rdquo;",
"      <i>",
"       Acta Radiol",
"      </i>",
"      , 2001, 42(3):339-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/11350296/pubmed\" id=\"11350296\" target=\"_blank\">",
"        11350296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tremblay E, Th&eacute;rasse E, Thomassin-Naggara I, et al, \"Quality Initiatives: Guidelines for Use of Medical Imaging During Pregnancy and Lactation,\"",
"      <i>",
"       Radiographics",
"      </i>",
"      , 2012, 32(3):897-911.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/22403117/pubmed\" id=\"22403117\" target=\"_blank\">",
"        22403117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wang PI, Chong ST, Kielar AZ, et al, \"Imaging of Pregnant and Lactating Patients: Part 1, Evidence-Based Review and Recommendations,\"",
"      <i>",
"       AJR Am J Roentgenol",
"      </i>",
"      , 2012, 198(4):778-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/22451541/pubmed\" id=\"22451541\" target=\"_blank\">",
"        22451541",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Webb JA, Thomsen HS, and Morcos SK, \"The Use of Iodinated and Gadolinium Contrast Media During Pregnancy and Lactation,\"",
"      <i>",
"       Eur Radiol",
"      </i>",
"      , 2005, 15(6):1234-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?12/61/13269/abstract-text/15609057/pubmed\" id=\"15609057\" target=\"_blank\">",
"        15609057",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9085 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-E8883B2495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13269=[""].join("\n");
var outline_f12_61_13269=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083943\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6893002\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10053613\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083948\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083979\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083980\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083981\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083982\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083988\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083946\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083983\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083968\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083949\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12933057\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083944\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083959\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083955\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083956\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299382\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7273313\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083950\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083951\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083953\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083954\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321927\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083986\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707697\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083969\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7083971\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9085\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9085|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/3/14388?source=related_link\">",
"      Gadoxetate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13270="Pityriasis rubra pilaris follicular papules";
var content_f12_61_13270=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Pityriasis rubra pilaris",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 406px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follicular papules and red-orange plaques in pityriasis rubra pilaris.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13270=[""].join("\n");
var outline_f12_61_13270=null;
var title_f12_61_13271="General principles of asynchronous activation and preexcitation";
var content_f12_61_13271=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   General principles of asynchronous activation and preexcitation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Bradley P Knight, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13271/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/61/13271/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal electrical activation of the right and left ventricles during the cardiac cycle follows a precisely defined pattern. After an impulse emerges from the atrioventricular (AV) node, it traverses the His bundle, and propagates down the bundle branches and the fascicles of the bundle branches to the terminal Purkinje fibers and ultimately the ventricular myocardium.",
"   </p>",
"   <p>",
"    Conduction abnormalities are generally due to asynchronous activation of the ventricles. This problem can be induced by one of two mechanisms: delayed activation of an area of the ventricles or early activation (preexcitation) of an area of the ventricles.",
"   </p>",
"   <p>",
"    This topic will present an overview of asynchronous activation and preexcitation. The clinical manifestations of abnormal activation or preexcitation are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=see_link\">",
"     \"Left anterior fascicular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=see_link\">",
"     \"Left posterior fascicular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DELAYED ACTIVATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed activation producing asynchronous activation may be a result of anatomic abnormalities or of physiologic properties of the cardiac tissues. Activation delay may occur between the ventricles or portions of the ventricles (interventricular delay), within the terminal Purkinje fibers",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventricular myocardium (intraventricular delay) or between layers of the heart (intramural delay) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, conduction delay causing asynchronous ventricular activation is usually manifest as an abnormal QRS complex on the electrocardiogram (ECG). Specific ECG patterns that are clinically distinguished include right bundle branch block (RBBB), left bundle branch block (LBBB), a prolonged QRS complex without specific features of LBBB or RBBB (usually called \"intraventricular conduction delay\" or IVCD), left anterior hemiblock, and left posterior hemiblock. While all of these conduction patterns are sometimes referred to collectively as forms of intraventricular conduction delay, the precise location of the conduction disturbance cannot be reliably determined from the surface ECG. In the case of RBBB and LBBB, it is probably more accurate to refer to these entities as forms of \"interventricular conduction delay.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Interventricular conduction delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed or blocked conduction in the bundles or their fascicles results in asynchronous activation and repolarization of the right and left ventricles. This, in turn, gives rise to characteristic electrocardiographic patterns. The classic examples of interventricular conduction delay are right and left bundle branch block. Fascicular block is not strictly an interventricular conduction delay, but results from a conduction disturbance in the left anterior or posterior fascicle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=see_link\">",
"     \"Right bundle branch block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=see_link\">",
"     \"Left bundle branch block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Intraventricular and intramural conduction delay",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular conduction delay is a delay within the myocardium itself. This occurs commonly in cardiomyopathies, resulting in regional differences in the time to peak systolic contraction. Intramural delay is a delay in activation between the endocardium and myocardium, also commonly noted in cardiomyopathies. Both intraventricular and intramural conduction delays occur together with interventricular left bundle branch block.",
"   </p>",
"   <p>",
"    The term parietal block has been used to describe conduction delays in the terminal Purkinje conduction system. This phenomenon may result in a QRS duration in ECG leads V1 to V3 that significantly exceeds the QRS duration in leads V4 to V6 (right ventricular parietal block) or vice versa (left ventricular parietal block). Right ventricular parietal block is seen in some patients with arrhythmogenic right ventricular cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Genesis of ECG pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two factors, magnitude and duration, determine the electrocardiographic (ECG) changes seen with a given type of block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Magnitude",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude (or amplitude) of the extracellular signal generated by the wavefront of unopposed dipoles can be affected by a number of factors. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A gain of force as with ventricular enlargement",
"     </li>",
"     <li>",
"      A loss of force as with myocardial infarction",
"     </li>",
"     <li>",
"      A change in cancellation due to asynchrony that can increase or decrease unopposed dipoles",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With regard to cancellation, the term \"activation\" is used to describe those unopposed boundaries that result in an electrocardiographically recorded potential. Many other wavefronts exist, however, and \"cancel\" each other. Normal synchronous ventricular depolarization results in a predictable sequence of opposed and unopposed wavefronts that result in the normal ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Asynchronous activation generally reduces the amount of signal cancellation, resulting in a larger extracellularly recorded electrogram. With left bundle block, for example, left ventricular activation is delayed, occurring later than activation of the right bundle. As a result, the left ventricular signal is not partially canceled by that from the right ventricle, leading to an increase in amplitude of the QRS complex. This is the reason that standard voltage criteria for ventricular enlargement are invalid in bundle branch blocks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asynchronous activation can also affect the duration of the recorded potential. The time of initiation of activation is unchanged in this setting, but termination is delayed due to slower conduction to the blocked ventricle. The net effect is increased duration of the P wave or QRS complex, depending upon the site of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PREEXCITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular preexcitation can occur when there is a ventricular premature beat or when ventricular pacing occurs before the expected timing of ventricular activation through the atrioventricular (AV) node. Ventricular pacing causes asynchronous activation due to preexcitation of either ventricle. Right ventricular pacing preexcites the right ventricle and causes a pattern that has some of the electrocardiographic features of left bundle branch block; left ventricular pacing preexcites the left ventricle and has some of the electrocardiographic features of a right bundle branch block. Preexciting the ventricles with pacing is used in patients with an intraventricular conduction delay and congestive heart failure to resynchronize the ventricles and improve mechanical synchrony. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=see_link\">",
"     \"Cardiac resynchronization therapy in heart failure: Implantation and other considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Preexciting the right ventricle with right ventricular pacing can be used to intentionally induce mechanical dyssynchrony. This has been used to reduce the outflow tract gradient in patients with hypertrophic cardiomyopathy and an outflow tract obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=see_link&amp;anchor=H14#H14\">",
"     \"Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy\", section on 'Dual chamber pacing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the term \"ventricular preexcitation\" is usually used to refer to preexcitation of the ventricle caused by AV conduction over an accessory pathway. The preexcitation syndromes are conditions in which atrial activation of the ventricles occurs earlier than would be expected if atrioventricular conduction occurred normally through the AV node.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General anatomic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of conducting pathways have been described (",
"    <a class=\"graphic graphic_table graphicRef53343 \" href=\"UTD.htm?26/0/26635\">",
"     table 1",
"    </a>",
"    ). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Accessory atrioventricular connections, often called",
"      <strong>",
"       Kent bundles",
"      </strong>",
"      in the older literature, which directly connect the atria and ventricles [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      James fibers, which connect the atria with the low AV node (atrionodal accessory pathway) or the bundle of His (atriofascicular accessory pathway) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      So-called Mahaim fibers of several types that arise from the atrium and insert into a bundle branch (atriofascicular), arise from the AV node and insert into a bundle branch (nodofascicular), arise from the AV node and insert into ventricular tissue (nodoventricular accessory pathways), or from one of the bundle branches and insert into ventricular tissue (fasciculoventricular accessory pathway) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/8-11\">",
"       8-11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Terminology based upon anatomic connections is gradually replacing the venerable eponyms and some attempt has been made at standardization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/8\">",
"     8",
"    </a>",
"    ]. The European Study Group for Preexcitation suggests that the term \"connection\" should be used to describe pathways that insert into ventricular myocardium while \"tracts\" should be applied to pathways that insert into specialized conduction tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the terms are often used interchangeably and tract is increasingly replacing connection (",
"    <a class=\"graphic graphic_table graphicRef53343 \" href=\"UTD.htm?26/0/26635\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Atrioventricular accessory pathways (connections)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ninety-five percent of atrioventricular accessory pathways conduct rapidly and have the characteristics of INa (sodium) dependent phase 0 action potentials that occur in normal \"fast response\" myocardium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=see_link\">",
"     \"Myocardial action potential and action of antiarrhythmic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five percent show decremental conduction, the mechanism of which is uncertain. Possible explanations include geometric factors, partial inactivation of the sodium channel, or perhaps dependence on a calcium channel. The fast response pathways often have short refractory periods and can conduct frequently. This poses a particular problem in rapid supraventricular tachycardias such as atrial flutter, which may conduct 1:1, and atrial fibrillation, which may produce ventricular flutter and fibrillation.",
"   </p>",
"   <p>",
"    In preexcitation syndromes in which the accessory pathway inserts eccentrically, the resultant ventricular depolarization represents a fusion between ventricular activation initiated by the fast response, rapidly conducting bypass pathway and that initiated by the slow response, slowly conducting atrioventricular node. This is the pattern characteristic of patients with the Wolff-Parkinson-White syndrome. The principles of this fusion are illustrated in Figure 2 (",
"    <a class=\"graphic graphic_figure graphicRef73740 graphicRef53773 graphicRef62454 \" href=\"UTD.htm?38/52/39752\">",
"     figure 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The PR interval is shortened due to the preexcitation.",
"     </li>",
"     <li>",
"      The eccentric ventricular activation results in a slurred upstroke of the QRS or delta wave.",
"     </li>",
"     <li>",
"      The QRS duration is increased due to the asynchronous activation between the preexcited and normally excited portions of the ventricular myocardium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    How the electrocardiogram can be used to identify the location of the accessory pathway is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     James fibers (intronodal or atrionodal bypass tract)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Lown-Ganong-Levine syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Lown-Ganong-Levine syndrome is characterized by palpitations in patients with an ECG that shows a short PR interval and a normal QRS duration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/13\">",
"     13",
"    </a>",
"    ]. For many years, this disorder was thought to be due to tracts that connected the atrium with the low AV node or the His bundle (via James fibers) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=see_link\">",
"     \"Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The current concept, however, is that the short PR interval with a normal QRS pattern results, in most cases, from enhanced or accelerated AV nodal conduction and less often from an accessory pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/12,14-16\">",
"     12,14-16",
"    </a>",
"    ]. A short PR interval appears to be more frequent in patients with concealed accessory pathways, but has also been associated with dual pathway physiology and AV nodal reentrant tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/15\">",
"     15",
"    </a>",
"    ]. However, only patients with symptomatic tachyarrhythmias are studied electrophysiologically. As a result, it is uncertain whether all individuals with a short PR interval and normal QRS complex have enhanced AV nodal conduction or accessory pathways near the AV node. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10853?source=see_link\">",
"     \"Concealed accessory pathways\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Reentrant SVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case of incessant supraventricular tachycardia (SVT), which continued despite AV block, has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/17\">",
"     17",
"    </a>",
"    ]. An atrial tachycardia, AV nodal reentrant tachycardia, and an orthodromic tachycardia using a concealed accessory AV pathway were excluded as causes. The earliest retrograde atrial activation was at the posterolateral tricuspid annulus, and the tachycardia was eliminated by ablation at this site. These observations strongly suggest a concealed atrionodal pathway as the cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Role of Mahaim fibers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mahaim pathways arise from the atria, AV node, fascicle, or one of the bundle branches and insert into fascicle or ventricular tissue. The precise characteristics of Mahaim fibers have been debated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/10\">",
"     10",
"    </a>",
"    ]. It was presumed that certain of these pathways, in which the AV node was normally traversed, could explain the situation in which the PR interval was normal but the QRS was widened (presumably due to eccentric activation of the ventricles) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/18\">",
"     18",
"    </a>",
"    ]. Some patients also had a prolonged PR interval with eccentric ventricular activation. This could be explained by slowed AV nodal conduction and anomalous connections at the level of or below the AV node.",
"   </p>",
"   <p>",
"    However, surgical and catheter ablation studies suggest that electrophysiologic characteristics attributed to nodoventricular Mahaim fibers are due to atriofascicular accessory connections with decremental conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. One report, for example, suggests the presence of an atrioventricular connection in the tricuspid ring [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/21\">",
"     21",
"    </a>",
"    ]. This connection has slow and rate-dependent conduction, blocks with adenosine, has intrinsic automaticity, and links to a rapidly conducting insulated pathway that generates a \"His-like\" potential. Despite these observations, some experts still believe that nodofascicular tracts exist and are functional [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/12\">",
"     12",
"    </a>",
"    ]. An orthodromic AVRT with atrioventricular dissociation has been presented as evidence for a nodoventricular type of Mahaim fiber [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fasciculoventricular pathways can be demonstrated in 1 to 2 percent of adults who show ventricular preexcitation and are referred for electrophysiologic investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. Enhanced AV nodal conduction with a short AH interval is common, but normal AH interval lengthening may occur during incremental atrial pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/11,26\">",
"     11,26",
"    </a>",
"    ]. The administration of adenosine may help to reveal the relationship between the fasciculoventricular pathway and its connection to the AV node and the infranodal conduction system. With AV nodal connections, a high degree of AV block or even complete AV block may occur with preexcited conducted beats.",
"   </p>",
"   <p>",
"    Familial Mahaim syndrome has been reported and suggests possible genetic transmission in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Classification of arrhythmias associated with accessory pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;The accessory pathways have two effects which facilitate the development of certain supraventricular tachyarrhythmias: they can provide a pathway for reentry; and they can produce preexcitation, which results in a wide complex tachycardia.",
"   </p>",
"   <p>",
"    The atrioventricular reentrant tachycardias (AVRT) can utilize both the AV node and an accessory pathway in the reentrant circuit. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Orthodromic AVRT, the most common form, uses a circuit consisting of antegrade conduction through the AV node and retrograde conduction through the accessory pathway. In the absence of preexisting or functional bundle branch block, this produces a narrow QRS tachycardia in which the P wave follows the QRS complex (",
"      <a class=\"graphic graphic_figure graphicRef71302 \" href=\"UTD.htm?15/35/15926\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The less common, or antidromic, form of AVRT conducts antegrade through the accessory pathway and retrograde through the AV node, producing a wide QRS complex with a delta wave and a P wave that follows the QRS complex. This would be a reentrant form of a \"preexcited tachycardia\" that uses the AV node (see below) (",
"      <a class=\"graphic graphic_figure graphicRef50433 \" href=\"UTD.htm?34/52/35655\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The permanent form of junctional reciprocating tachycardia is a variant of AVRT. It uses anomalous connections as evidenced by successful interruption of the arrhythmia after ablation of the responsible accessory pathways [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13271/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As discussed above, the so-called James and Mahaim fibers may also be involved in reentrant arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Preexcited tachycardias",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preexcited tachycardias, such as the WPW syndrome, are wide complex tachycardias that conduct antegrade over the accessory pathway. They are induced by supraventricular tachycardias, including atrial fibrillation, atrial flutter, and the family of atrial tachycardias including the antidromic form of AVRT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=see_link\">",
"     \"Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=see_link\">",
"     \"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27490551\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Delayed activation producing asynchronous activation may be a result of anatomic abnormalities or of physiologic properties of the cardiac tissues. Clinically, conduction delay causing asynchronous ventricular activation is usually manifest as an abnormal QRS complex on the electrocardiogram (ECG). Specific ECG patterns that are clinically distinguished include right bundle branch block (RBBB), left bundle branch block (LBBB), a prolonged QRS complex without specific features of LBBB or RBBB (usually called \"intraventricular conduction delay\" or IVCD), left anterior hemiblock, and left posterior hemiblock. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Delayed activation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two factors, magnitude and duration, determine the electrocardiographic (ECG) changes seen with a given type of block. Normal synchronous ventricular depolarization results in a predictable sequence of opposed and unopposed wavefronts that results in the normal ECG. Asynchronous activation generally reduces the amount of signal cancellation, resulting in a larger extracellularly recorded electrogram. The time of initiation of activation is unchanged in the setting of asynchronous activation, but termination is delayed due to slower conduction to the blocked ventricle. The net effect is an increased duration of the P wave or QRS complex. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Genesis of ECG pattern'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ventricular preexcitation can occur when there is a ventricular premature beat or when ventricular pacing occurs before the expected timing of ventricular activation through the atrioventricular (AV) node. However, the term \"ventricular preexcitation\" is usually used to refer to preexcitation of the ventricle caused by AV conduction over an accessory pathway. The preexcitation syndromes are conditions in which atrial activation of the ventricles occurs earlier than would be expected if atrioventricular conduction occurred normally through the AV node. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Preexcitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of conducting pathways have been described, including those connecting the atria with the ventricles, the atria with the AV node, the atria with the His-Purkinje system, and the AV node with the ventricles (",
"      <a class=\"graphic graphic_table graphicRef53343 \" href=\"UTD.htm?26/0/26635\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'General anatomic considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The accessory pathways have two effects which facilitate the development of certain supraventricular tachyarrhythmias: they can provide a pathway for reentry; and they can produce preexcitation, which results in a wide complex tachycardia. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Classification of arrhythmias associated with accessory pathways'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/1\">",
"      Auricchio A, Fantoni C, Regoli F, et al. Characterization of left ventricular activation in patients with heart failure and left bundle-branch block. Circulation 2004; 109:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/2\">",
"      Durrer D, van Dam RT, Freud GE, et al. Total excitation of the isolated human heart. Circulation 1970; 41:899.",
"     </a>",
"    </li>",
"    <li>",
"     Van Dam RT, Janse MJ. Activation of the Heart. In: Comprehensive Electrocardiology: Theory and Practice in Health and Disease, MacFarlane P, Veitch Lawrie TD (Eds), Pergamon Press, New York 1980. p.101.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/4\">",
"      Kent AF. Researches on the structure and function of the mammalian heart. J Physiol 1893; 14:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/5\">",
"      Anderson RH, Becker AE, Brechenmacher C, et al. Ventricular preexcitation. A proposed nomenclature for its substrates. Eur J Cardiol 1975; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/6\">",
"      Boineau JP, Moore EN. Evidence for propagation of activation across an accessory atrioventricular connection in types A and B pre-excitation. Circulation 1970; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/7\">",
"      JAMES TN. Morphology of the human atrioventricular node, with remarks pertinent to its electrophysiology. Am Heart J 1961; 62:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/8\">",
"      MAHAIM I. Kent's fibers and the A-V paraspecific conduction through the upper connections of the bundle of His-Tawara. Am Heart J 1947; 33:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/9\">",
"      Lev M, Fox SM 3rd, Bharati S, et al. Mahaim and James fibers as a basis for a unique variety of ventricular preexcitation. Am J Cardiol 1975; 36:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/10\">",
"      Klein GJ, Guiraudon G, Guiraudon C, Yee R. The nodoventricular Mahaim pathway: an endangered concept? Circulation 1994; 90:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/11\">",
"      Sternick EB, Gerken LM, Vrandecic MO, Wellens HJ. Fasciculoventricular pathways: clinical and electrophysiologic characteristics of a variant of preexcitation. J Cardiovasc Electrophysiol 2003; 14:1057.",
"     </a>",
"    </li>",
"    <li>",
"     Josephson ME. Clinical Cardiac Electrophysiology: Techniques and Interpretations, 2d ed, Lea &amp; Febiger, Philadelphia 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/13\">",
"      LOWN B, GANONG WF, LEVINE SA. The syndrome of short P-R interval, normal QRS complex and paroxysmal rapid heart action. Circulation 1952; 5:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/14\">",
"      Denes P, Wu D, Amat-y-Leon F, et al. The determinants of atrioventricular nodal re-entrance with premature atrial stimulation in patients with dual A-V nodal pathways. Circulation 1977; 56:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/15\">",
"      Benditt DG, Pritchett LC, Smith WM, et al. Characteristics of atrioventricular conduction and the spectrum of arrhythmias in lown-ganong-levine syndrome. Circulation 1978; 57:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/16\">",
"      Bauernfeind RA, Swiryn S, Strasberg B, et al. Analysis of anterograde and retrograde fast pathway properties in patients with dual atrioventricular nodal pathways: observations regarding the pathophysiology of the Lown-Ganong-Levine syndrome. Am J Cardiol 1982; 49:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/17\">",
"      Zivin A, Morady F. Incessant tachycardia using a concealed atrionodal bypass tract. J Cardiovasc Electrophysiol 1998; 9:191.",
"     </a>",
"    </li>",
"    <li>",
"     Wellens HJJ. The preexcitation syndrome. In: Electrical Stimulation of the Heart, Wellens HJJ (Ed), University Park Press, Baltimore 1971. p.97.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/19\">",
"      Gillette PC, Garson A Jr, Cooley DA, McNamara DG. Prolonged and decremental antegrade conduction properties in right anterior accessory connections: Wide QRS antidromic tachycardia of left bundle branch block pattern without Wolff-Parkinson-White configuration in sinus rhythm. Am Heart J 1982; 103:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/20\">",
"      Klein GJ, Guiraudon GM, Kerr CR, et al. \"Nodoventricular\" accessory pathway: evidence for a distinct accessory atrioventricular pathway with atrioventricular node-like properties. J Am Coll Cardiol 1988; 11:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/21\">",
"      McClelland JH, Wang X, Beckman KJ, et al. Radiofrequency catheter ablation of right atriofascicular (Mahaim) accessory pathways guided by accessory pathway activation potentials. Circulation 1994; 89:2655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/22\">",
"      Cappato R, Schl&uuml;ter M, Mont L, Kuck KH. Anatomic, electrical, and mechanical factors affecting bipolar endocardial electrograms. Impact on catheter ablation of manifest left free-wall accessory pathways. Circulation 1994; 90:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/23\">",
"      Grogin HR, Lee RJ, Kwasman M, et al. Radiofrequency catheter ablation of atriofascicular and nodoventricular Mahaim tracts. Circulation 1994; 90:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/24\">",
"      Li HG, Klein GJ, Thakur RK, Yee R. Radiofrequency ablation of decremental accessory pathways mimicking \"nodoventricular\" conduction. Am J Cardiol 1994; 74:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/25\">",
"      Mantovan R, Verlato R, Corrado D, et al. Orthodromic tachycardia with atrioventricular dissociation: evidence for a nodoventricular (Mahaim) fiber. Pacing Clin Electrophysiol 2000; 23:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/26\">",
"      Gallagher JJ, Smith WM, Kasell JH, et al. Role of Mahaim fibers in cardiac arrhythmias in man. Circulation 1981; 64:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/27\">",
"      Ott P, Marcus FI. Familial Mahaim syndrome. Ann Noninvasive Electrocardiol 2001; 6:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13271/abstract/28\">",
"      Shih HT, Miles WM, Klein LS, et al. Multiple accessory pathways in the permanent form of junctional reciprocating tachycardia. Am J Cardiol 1994; 73:361.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 898 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-210.101.131.232-8A237B75EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13271=[""].join("\n");
var outline_f12_61_13271=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27490551\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DELAYED ACTIVATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Interventricular conduction delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Intraventricular and intramural conduction delay",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Genesis of ECG pattern",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Magnitude",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PREEXCITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General anatomic considerations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Atrioventricular accessory pathways (connections)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      James fibers (intronodal or atrionodal bypass tract)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Lown-Ganong-Levine syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Reentrant SVT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Role of Mahaim fibers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Classification of arrhythmias associated with accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Preexcited tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27490551\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/898\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/898|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/58/929\" title=\"figure 1A\">",
"      Accessory AV pathways I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/19/2353\" title=\"figure 1B\">",
"      Accessory AV pathways II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/55/2929\" title=\"figure 1C\">",
"      Accessory AV pathways III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/35/15926\" title=\"figure 2\">",
"      Orthodromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/52/35655\" title=\"figure 3\">",
"      Antidromic AVRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/898|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/0/26635\" title=\"table 1\">",
"      Terminology of preexcitation pathways",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39256?source=related_link\">",
"      Anatomy, pathophysiology and localization of accessory pathways in the preexcitation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24311?source=related_link\">",
"      Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/17/11545?source=related_link\">",
"      Cardiac resynchronization therapy in heart failure: Implantation and other considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10853?source=related_link\">",
"      Concealed accessory pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/31/16886?source=related_link\">",
"      Left anterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/54/39784?source=related_link\">",
"      Left bundle branch block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16420?source=related_link\">",
"      Left posterior fascicular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11272?source=related_link\">",
"      Lown-Ganong-Levine syndrome and enhanced atrioventricular nodal conduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/33/38422?source=related_link\">",
"      Myocardial action potential and action of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/21/7514?source=related_link\">",
"      Nonpharmacologic treatment of outflow obstruction in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/6/10344?source=related_link\">",
"      Right bundle branch block",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13272="Neuroendocrine high power";
var content_f12_61_13272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell neuroendocrine carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph showing cells with an organoid architecture. The cells have a modest amount of eosinophilic cytoplasm and nuclei with coarse chromatin and prominent nucleoli. An area of necrosis is seen in the lower right hand portion of the photomicrograph, which is characteristic of large cell neuroendocrine carcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13272=[""].join("\n");
var outline_f12_61_13272=null;
var title_f12_61_13273="Overview of the initial evaluation, treatment and prognosis of lung cancer";
var content_f12_61_13273=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the initial evaluation, treatment and prognosis of lung cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13273/contributors\">",
"     David E Midthun, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13273/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Joseph S Friedberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13273/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/61/13273/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cancer worldwide, with an estimated 1,600,000 new cases and 1,380,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States, there will be an estimated 228,000 new cases of lung cancer and 159,500 deaths in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both the absolute and relative frequency of lung cancer have risen dramatically. As an example, the age-adjusted death rate from lung cancer is similar to that of pancreatic cancer prior to 1930 for men (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032005.pdf\">",
"     Graph death rates",
"    </a>",
"    ) and prior to 1960 for women (",
"    <a class=\"external\" href=\"file://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-032006.pdf\">",
"     Graph death rates",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/3\">",
"     3",
"    </a>",
"    ]. Around 1953, lung cancer became the most common cause of cancer deaths in men, and in 1985 it became the leading cause of cancer deaths in women. Although lung cancer deaths have begun to decline in men, the death rate in women continues to rise, and almost one-half of all lung cancer deaths now occur in women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=see_link\">",
"     \"Women and lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term lung cancer, or bronchogenic carcinoma, refers to malignancies that originate in the airways or pulmonary parenchyma. Approximately 95 percent of all lung cancers are classified as either small cell lung cancer (SCLC) or non-small cell lung cancer (NSCLC). This distinction is required for staging, treatment, and prognosis. Other cell types comprise about 5 percent of malignancies arising in the lung.",
"   </p>",
"   <p>",
"    This discussion will present an overview of the initial diagnosis, treatment, and prognosis of patients with both NSCLC and SCLC. An overview of the risk factors, pathology, and clinical manifestations of lung cancer is presented separately, as is an overview of the management of patients with advanced NSCLC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=see_link\">",
"     \"Overview of the risk factors, pathology, and clinical manifestations of lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main issues to assess in a patient with a suspected lung cancer are the cell type (NSCLC versus SCLC), the stage of disease, and the functional status of the patient. These parameters are essential for appropriate patient management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A tissue diagnosis is necessary to determine whether a lung cancer is a NSCLC or an SCLC, as well as to rule out the possibility that disease represents lung metastasis from a primary tumor at another site. This information is critical for treatment planning.",
"     </li>",
"     <li>",
"      Staging for NSCLC is critical in determining the appropriate treatment for a patient with resectable disease and avoiding unnecessary surgery in advanced disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/4\">",
"       4",
"      </a>",
"      ]. Staging of NSCLC utilizes the tumor, node, metastasis (TNM) system (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74820 \" href=\"UTD.htm?19/43/20157\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef68104 \" href=\"UTD.htm?13/4/13388\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"       \"Diagnosis and staging of non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Staging of SCLC uses the Veterans Administration Lung Study Group designations of limited (confined to one hemithorax) or extensive (beyond one hemithorax) disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/5\">",
"       5",
"      </a>",
"      ]. This distinction is important since patients with limited disease may benefit from thoracic radiation therapy in addition to systemic chemotherapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link\">",
"       \"Pathobiology and staging of small cell carcinoma of the lung\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment of lung cancer, whether with surgery, chemotherapy, radiation therapy or a combination of these, can be associated with substantial toxicity. Patients with significant impairment due to their lung cancer or comorbid conditions may not be able to withstand resection or alternatively aggressive chemoradiotherapy. Performance status can be assessed by a variety of methods including the Karnofsky Performance Status (KPS) and the Eastern Cooperative Oncology Group Performance Scale (ECOG PS) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72901 \" href=\"UTD.htm?9/15/9467\">",
"       table 5",
"      </a>",
"      ). The KPS was introduced in the 1940s and uses a 100-point scale and 11 measures to describe patient's abilities to pursue activities and perform work [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/6\">",
"       6",
"      </a>",
"      ]. The ECOG PS uses a five-point scale and has been shown in a comparative study to be a better predictor of prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diagnostic procedures and staging should be carried out simultaneously, even though it may be tempting to simply pursue a diagnosis when an obvious abnormality is present on imaging. As an example, in a patient with a 4 cm lung mass and mediastinal adenopathy on CT, a mediastinal node biopsy may provide a diagnosis and confirm N2 (IIIA) disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59166 \" href=\"UTD.htm?22/33/23060\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef80405 \" href=\"UTD.htm?25/12/25800\">",
"     picture 1",
"    </a>",
"    ). In contrast, a transthoracic needle aspirate of the mass may provide a tissue diagnosis but does not stage the mediastinum. This can lead to the inappropriate assumption that mediastinal lymph nodes are involved or necessitate a second procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NSCLC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid advances in understanding the molecular pathogenesis of NSCLC have clearly demonstrated that this is a heterogeneous group of diseases. Although the initial treatment of localized disease is the same, the molecular characterization of tumor tissue in patients with NSCLC can serve as a guide to treatment both in those who present with metastatic disease and in those who relapse after primary therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Currently defined NSCLC subsets for which specific targeted therapies have been developed include those with mutations in the epidermal growth factor receptor (EGFR) and those with the EML4-ALK fusion oncogene. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"     \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"     \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection offers the best opportunity for long-term survival and cure in patients with resectable NSCLC. The appropriateness of surgical resection of candidates with known or suspected NSCLC includes preoperative staging and an assessment of performance status with concurrent comorbidities and pulmonary function to allow prediction of postoperative function.",
"   </p>",
"   <p>",
"    A patient with lung cancer may be \"resectable\" by virtue of having a surgically removable NSCLC, but may not be \"operable\" due to poor pulmonary function or comorbidities. Advances in surgical technique, the role of limited resection, and postoperative care may provide the opportunity for surgical resection in patients who previously might not have been considered candidates for aggressive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=see_link\">",
"     \"Preoperative evaluation for lung resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with stage I or II NSCLC should be treated with complete surgical resection whenever possible (",
"      <a class=\"graphic graphic_picture graphicRef76620 \" href=\"UTD.htm?3/27/3511\">",
"       picture 2",
"      </a>",
"      ). Postoperative adjuvant chemotherapy has been shown to improve survival in patients with pathologic stage II disease and may have a role for patients with stage IB NSCLC (",
"      <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link\">",
"       \"Management of stage I and stage II non-small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with stage I or II disease who are not candidates for surgical resection or who refuse surgery may be candidates for radiotherapy. Radiotherapy may be applied by conventional means, stereotactic radiosurgery, or radiofrequency ablation. Photodynamic therapy may also be useful as a primary treatment modality in carefully selected patients with superficial airway lesions (",
"      <a class=\"graphic graphic_picture graphicRef76620 \" href=\"UTD.htm?3/27/3511\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=see_link&amp;anchor=H10#H10\">",
"       \"Management of stage I and stage II non-small cell lung cancer\", section on 'Nonsurgical approaches'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=see_link\">",
"       \"Photodynamic therapy of lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with pathologically proven stage III disease prior to definitive therapy, a combined modality approach using concurrent chemotherapy is generally preferred. The role of surgery following chemoradiotherapy is an area of active investigation. Surgery may also retain a role for carefully selected patients with T3 or T4 lesions and negative mediastinal lymph nodes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=see_link\">",
"       \"Management of stage III non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with clinical stage I or II disease, in whom tumor involvement of mediastinal lymph nodes (pathologic stage IIIA) is documented in the histologic evaluation of the surgical resection specimen, adjuvant chemotherapy has been shown to improve survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"       \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with stage IV disease are generally treated with systemic therapy or a symptom-based palliative approach. In appropriately selected patients, chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      molecularly targeted therapy may prolong survival without sacrificing quality of life. Radiation therapy and surgery may also be useful for symptom palliation in some patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with stage IV disease based upon the presence of an isolated metastasis (eg, brain, adrenal) may benefit from resection of the metastasis as well as aggressive treatment of the primary tumor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/8\">",
"       8",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=see_link\">",
"       \"Treatment of brain metastases in favorable prognosis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Local palliative measures may be useful in patients with uncontrolled pulmonary disease [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/9\">",
"       9",
"      </a>",
"      ]. Dyspnea due to bulky central airway involvement may be palliated by rigid or flexible bronchoscopic removal of tumor using laser for coagulation or cryotherapy. Stenting may be necessary to maintain airway patency and allow external beam radiation. Brachytherapy can be applied locally by a bronchoscopy-directed catheter placement and may be helpful for recurrent or persistent disease in the airway. This approach is usually pursued after maximal external beam radiation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=see_link\">",
"       \"Diagnosis and management of central airway obstruction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Prognosis of NSCLC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Stage of disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The TNM stage at presentation in patients with NSCLC has the greatest impact on the prognosis.",
"   </p>",
"   <p>",
"    The most extensive data relating stage to prognosis come from a validation series of over 31,000 cases from the Surveillance, Epidemiology and End Results (SEER) database used to validate the 7th TNM staging system [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/10\">",
"     10",
"    </a>",
"    ]. Survival decreased progressively with more advanced disease from a median of 59 months for patients with stage IA disease to four months for those with stage IV disease (",
"    <a class=\"graphic graphic_figure graphicRef73088 \" href=\"UTD.htm?16/30/16871\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=see_link\">",
"     \"Diagnosis and staging of non-small cell lung cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system for non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Clinical parameters",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other clinical factors that exist at the time of diagnosis that can predict survival independent of the disease stage. Most of these factors were identified in studies that primarily included patients with advanced or inoperable NSCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performance status &mdash; Poor performance status and weight loss have been associated with shortened survival [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/11-16\">",
"       11-16",
"      </a>",
"      ]. Reduced appetite, a precursor of weight loss, also has negative prognostic implications [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ethnicity &mdash; African American ethnicity does not appear to be an independent predictor of poorer survival. Although some studies suggested that African Americans have a worse prognosis even after correcting for stage and treatment, a multivariate analysis indicated that performance status and weight loss account for these results [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227009694\">",
"    <span class=\"h3\">",
"     Histopathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of patients with NSCLC have given conflicting results as to whether the distinction between adenocarcinoma and squamous cell carcinoma affects prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Other pathologic factors that have been linked to prognosis in some studies include the degree of differentiation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and lymphatic invasion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link\">",
"     \"Pathology of lung malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each histologic subtype can vary in its degree of differentiation. The impact of tumor differentiation on resectable NSCLC is uncertain. Some studies indicate that poorly differentiated tumors have a worse prognosis than better differentiated tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. However, this finding has not been universal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lymphatic vessel invasion has a negative impact on outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. In one study of 244 patients who had resected stage I NSCLC, five-year cancer-free survival was higher among patients without lymphatic vessel invasion (74 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of microscopic vascular invasion (MVI) also has a negative impact on survival in patients with resected",
"    <span class=\"nowrap\">",
"     T1/T2",
"    </span>",
"    N0 lesions (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"UTD.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The importance of this finding was illustrated by a single institution series of 746 patients, in which MVI was present in 257 (34 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/28\">",
"     28",
"    </a>",
"    ]. On multivariant analysis, the five-year survival rate was significantly increased in those without MVI (65 versus 55 percent).",
"   </p>",
"   <p>",
"    Occult lymph node metastasis can be detected by immunohistochemistry, and one large study has correlated the presence of such micrometastases with a poorer long-term outcome in patients with stage I disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=see_link\">",
"     \"Adjuvant systemic therapy in resectable non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reverse transcriptase polymerase chain reaction (RT-PCR) has also been used to detect tumor markers in lymph nodes from patients with NSCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/31\">",
"     31",
"    </a>",
"    ]. However, such studies are limited by lack of laboratory standardization and reproducibility, although the clinical significance of this finding based upon RT-PCR will remain uncertain until long-term studies are reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1227009681\">",
"    <span class=\"h3\">",
"     Molecular characterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contemporary studies have identified various molecular abnormalities that allow the characterization of particular subsets of patients with NSCLC. This subclassification has important implications for personalizing patient care and may define patient categories with differing prognoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific, targeted therapies are available for patients with two different molecular subsets of NSCLC:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activating mutations in the epidermal growth factor receptor (EGFR) define a subset of patients with adenocarcinoma that typically affects patients who are never smoking, women,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      of Asian ethnicity. These patients are generally highly responsive to EGFR tyrosine kinase inhibitors (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      ) and have a significantly better prognosis than those without EGFR mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/32\">",
"       32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=see_link\">",
"       \"Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of the EML4-ALK fusion oncogene defines another NSCLC subset that is more frequent in nonsmokers or former smokers and occurs at a younger age. These patients are highly responsive to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      , an inhibitor of the anaplastic lymphoma kinase (ALK). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     PET and PET-CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET), alone or integrated with computed tomography (CT), is useful in the initial staging to identify sites of tumor involvement. Integrated PET-CT has been shown to improve staging over PET scanning alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=see_link&amp;anchor=H10#H10\">",
"     \"Role of imaging in the staging of non-small cell lung cancer\", section on 'Positron emission tomography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A tumor's metabolic activity can be measured using the standardized uptake value (SUV) to assess the tumor uptake of fluorodeoxyglucose. A meta-analysis, based upon 21 retrospective studies that included 2637 patients with stages I to IV NSCLC, found that a high SUV was associated with a poor prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/34\">",
"     34",
"    </a>",
"    ]. A second meta-analysis, limited to patients with stage I NSCLC, also found that a lower FDG uptake was associated with a better prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/35\">",
"     35",
"    </a>",
"    ]. PET (or PET-CT) may also be useful in predicting response to chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/36-38\">",
"     36-38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional studies are needed to establish the role of SUV as a prognostic tool or in predicting the response to treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Recurrence after complete resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo a complete resection for NSCLC may develop recurrent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease. Multiple factors influence survival following disease recurrence.",
"   </p>",
"   <p>",
"    In a series of 1073 patients who underwent a complete resection, recurrent NSCLC was identified in 445 patients (41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/39\">",
"     39",
"    </a>",
"    ]. The median time to recurrence following surgery was 11.5 months, and the median survival following recurrence was 8.1 months. Multivariate analysis identified several factors that predicted shorter survival following recurrence. These included poor performance status, disease-free interval of one year or less, prior use of neoadjuvant chemotherapy or adjuvant radiation therapy, and distant metastases (as opposed to intrathoracic recurrence alone).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SCLC",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCLC is a disseminated disease in most patients, even at presentation. Thus systemic chemotherapy is an integral part of the initial treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with limited stage disease are primarily treated with a combination of chemotherapy and radiation therapy, since the addition of radiation therapy has been shown to prolong survival compared to chemotherapy therapy alone. Surgery is not used except in the rare patient who presents with a solitary pulmonary nodule without metastases or regional lymph node involvement. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=see_link\">",
"       \"Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=see_link\">",
"       \"Role of surgery in multimodality therapy for small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with extensive stage SCLC, chemotherapy alone is used as the initial therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prophylactic radiation has been shown to decrease the incidence of brain metastases and prolong survival in patients with both limited and extensive stage SCLC who respond to their initial treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=see_link\">",
"       \"Prophylactic cranial irradiation for patients with small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important prognostic factor in patients with lung cancer is the stage of disease at presentation. The primary determinant of survival in patients with SCLC is the extent of disease at presentation. For patients with limited stage disease, median survivals range from 15 to 20 months, and the reported five-year survival rate is 10 to 13 percent. In contrast, for patients with extended stage disease, the median survival is 8 to 13 months, and the five-year survival rate is 1 to 2 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=see_link&amp;anchor=H2#H2\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Benefit of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical parameters also have prognostic importance in patients with SCLC [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13273/abstract/16\">",
"     16",
"    </a>",
"    ]. Poor performance status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    weight loss have been associated with shortened survival.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both curative and palliative treatment of lung cancer often involve multimodality approaches that may include surgery, radiation therapy, and systemic therapy with cytotoxic chemotherapy or molecularly targeted agents. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'SCLC'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The side effects of systemic therapy are often of particular concern, because of their potential negative effects on quality of life both during and after treatment. The toxicities will vary depending upon the therapeutic regimen.",
"   </p>",
"   <p>",
"    Common toxicities observed in patients being treated for lung cancer include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy-induced nausea and vomiting of variable severity may be seen with most chemotherapy regimens (",
"      <a class=\"graphic graphic_table graphicRef58756 \" href=\"UTD.htm?7/23/7549\">",
"       table 6",
"      </a>",
"      ), but can usually be prevented or managed effectively with aggressive therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=see_link\">",
"       \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"       \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hematologic toxicity, including in particular anemia and neutropenia with an increased risk of infection, is seen with most cytotoxic chemotherapy regimens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=see_link\">",
"       \"Hematologic consequences of malignancy: Anemia and bleeding\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nephrotoxicity, especially with chemotherapy regimens containing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      , can be severe. Intensive hydration is required to prevent this complication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=see_link\">",
"       \"Cisplatin nephrotoxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurotoxicity, which is especially frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and the taxanes (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      ), is usually at least partially reversible after therapy is discontinued. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=see_link\">",
"       \"Neurologic complications of non-platinum cancer chemotherapy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=see_link\">",
"       \"Neurologic complications of platinum-based chemotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fatigue is frequent and may be due to systemic chemotherapy, radiation therapy, or the cancer itself. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=see_link\">",
"       \"Cancer-related fatigue: Prevalence, screening and clinical assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cutaneous toxicity, manifested as an acneiform rash, is frequent with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      . Although this side effect is troublesome, the presence of a rash is correlated with a response to therapy.",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/58/30631?source=see_link\">",
"       crizotinib",
"      </a>",
"      is usually well tolerated; visual disturbances (photophobia, flashes of light, decreased visual acuity, blurred vision) are the most common side effects. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=see_link&amp;anchor=H272520708#H272520708\">",
"       \"Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer\", section on 'Toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Anorexia and weight loss are common in patients with lung cancer, and may be due to the disease or its treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=see_link\">",
"       \"Clinical features and pathogenesis of cancer cachexia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link\">",
"       \"Pharmacologic management of cancer anorexia/cachexia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=see_link\">",
"       \"Patient information: Lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=see_link\">",
"       \"Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung cancer is the most common cause of cancer mortality worldwide for both men and women.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The initial stage in management is to assess whether the patient has a NSCLC or a SCLC, the stage of the disease, and the overall performance status of the patient. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with NSCLC, initial management is largely determined by the stage of disease. For patients with early stage disease, surgical resection offers the best opportunity for cure, while concurrent chemoradiotherapy is preferred for those with more extensive intrathoracic disease. In contrast, patients with advanced disease are managed palliatively with systemic therapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      local palliative modalities. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'NSCLC'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with SCLC, systemic chemotherapy is an important component of treatment, because SCLC is disseminated at presentation in almost all patients. For those with limited stage disease, thoracic radiation therapy is used in combination with chemotherapy. Prophylactic cranial irradiation is often used to decrease the incidence of brain metastases and prolong survival. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'SCLC'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/3\">",
"      Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/4\">",
"      Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123:147S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/5\">",
"      Havemann K, Hirsch FR, Ihde DC, et al. Staging and prognostic factors in small cell lung cancer: a consensus report. Lung Cancer 1989; 5:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/6\">",
"      Karnofsky D, Abelmann W, Craver L, Burchenal J. The use of nitrogen mustard in the palliative treatment of cancer. Cancer 1948; 1:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/7\">",
"      Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: a prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/8\">",
"      Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol 2008; 26:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/9\">",
"      Kvale PA, Simoff M, Prakash UB, American College of Chest Physicians. Lung cancer. Palliative care. Chest 2003; 123:284S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/10\">",
"      Groome PA, Bolejack V, Crowley JJ, et al. The IASLC Lung Cancer Staging Project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/11\">",
"      Hoang T, Xu R, Schiller JH, et al. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/12\">",
"      Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 2002; 94:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/13\">",
"      Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/14\">",
"      FEINSTEIN AR. SYMPTOMATIC PATTERNS, BIOLOGIC BEHAVIOR, AND PROGNOSIS IN CANCER OF THE LUNG. PRACTICAL APPLICATION OF BOOLEAN ALGEBRA AND CLINICAL TAXONOMY. Ann Intern Med 1964; 61:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/15\">",
"      Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010; 5:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/16\">",
"      Sculier JP, Chansky K, Crowley JJ, et al. The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the proposals for the 7th Edition. J Thorac Oncol 2008; 3:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/17\">",
"      Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer. A report from the Lung Cancer Study Group. Cancer 1984; 54:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/18\">",
"      Postoperative T1 N0 non-small cell lung cancer. Squamous versus nonsquamous recurrences. The Lung Cancer Study Group. J Thorac Cardiovasc Surg 1987; 94:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/19\">",
"      Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer 1995; 76:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/20\">",
"      Pairolero PC, Williams DE, Bergstralh EJ, et al. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/21\">",
"      Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995; 109:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/22\">",
"      Lipford EH 3rd, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited-stage, nonsmall cell carcinoma of the lung. Am J Surg Pathol 1984; 8:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/23\">",
"      Takise A, Kodama T, Shimosato Y, et al. Histopathologic prognostic factors in adenocarcinomas of the peripheral lung less than 2 cm in diameter. Cancer 1988; 61:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/24\">",
"      Cagini L, Monacelli M, Giustozzi G, et al. Biological prognostic factors for early stage completely resected non-small cell lung cancer. J Surg Oncol 2000; 74:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/25\">",
"      Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998; 16:2468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/26\">",
"      Shields TW. Prognostic significance of parenchymal lymphatic vessel and blood vessel invasion in carcinoma of the lung. Surg Gynecol Obstet 1983; 157:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/27\">",
"      Macchiarini P, Fontanini G, Hardin MJ, et al. Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg 1993; 106:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/28\">",
"      Ruffini E, Asioli S, Filosso PL, et al. Significance of the presence of microscopic vascular invasion after complete resection of Stage I-II pT1-T2N0 non-small cell lung cancer and its relation with T-Size categories: did the 2009 7th edition of the TNM staging system miss something? J Thorac Oncol 2011; 6:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/29\">",
"      Naito Y, Goto K, Nagai K, et al. Vascular invasion is a strong prognostic factor after complete resection of node-negative non-small cell lung cancer. Chest 2010; 138:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/30\">",
"      Rusch VW, Hawes D, Decker PA, et al. Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol 2011; 29:4313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/31\">",
"      Xi L, Coello MC, Litle VR, et al. A combination of molecular markers accurately detects lymph node metastasis in non-small cell lung cancer patients. Clin Cancer Res 2006; 12:2484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/32\">",
"      D'Angelo SP, Janjigian YY, Ahye N, et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib. J Thorac Oncol 2012; 7:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/33\">",
"      De Wever W, Ceyssens S, Mortelmans L, et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007; 17:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/34\">",
"      Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project. J Thorac Oncol 2010; 5:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/35\">",
"      Nair VS, Krupitskaya Y, Gould MK. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 2009; 4:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/36\">",
"      Lowe VJ, Hoffman JM, DeLong DM, et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. J Nucl Med 1994; 35:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/37\">",
"      P&ouml;ttgen C, Levegr&uuml;n S, Theegarten D, et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006; 12:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/38\">",
"      Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:8362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13273/abstract/39\">",
"      Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection. Ann Thorac Surg 2007; 83:409.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4639 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-0AA24E0359-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13273=[""].join("\n");
var outline_f12_61_13273=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NSCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Prognosis of NSCLC",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Stage of disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Clinical parameters",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1227009694\">",
"      - Histopathology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1227009681\">",
"      - Molecular characterization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - PET and PET-CT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Recurrence after complete resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SCLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SIDE EFFECTS OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4639\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4639|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/33/23060\" title=\"diagnostic image 1\">",
"      NSCLC RUL mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4639|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/30/16871\" title=\"figure 1\">",
"      Nonsmall cell lung ca survival by TNM gp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4639|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/12/25800\" title=\"picture 1\">",
"      NSCLC pos cytotology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/27/3511\" title=\"picture 2\">",
"      Sq ca lung in situ bronch",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4639|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/43/20157\" title=\"table 2\">",
"      Lung cancer TMN staging 6th edition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/4/13388\" title=\"table 3\">",
"      Changes 7th ed TNM lung ca",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 4\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/15/9467\" title=\"table 5\">",
"      ECOG performance scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/23/7549\" title=\"table 6\">",
"      Emetogenicity chemo drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17833?source=related_link\">",
"      Adjuvant systemic therapy in resectable non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/31/40440?source=related_link\">",
"      Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/62/11242?source=related_link\">",
"      Cancer-related fatigue: Prevalence, screening and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9914?source=related_link\">",
"      Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29833?source=related_link\">",
"      Cisplatin nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17960?source=related_link\">",
"      Clinical features and pathogenesis of cancer cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/30/37351?source=related_link\">",
"      Diagnosis and management of central airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14841?source=related_link\">",
"      Diagnosis and staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23914?source=related_link\">",
"      Hematologic consequences of malignancy: Anemia and bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31816?source=related_link\">",
"      Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/5/1114?source=related_link\">",
"      Management of stage I and stage II non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/36/39498?source=related_link\">",
"      Management of stage III non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/32/43530?source=related_link\">",
"      Neurologic complications of non-platinum cancer chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37242?source=related_link\">",
"      Neurologic complications of platinum-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/57/16282?source=related_link\">",
"      Overview of the risk factors, pathology, and clinical manifestations of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/34/35363?source=related_link\">",
"      Patient information: Lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/3/1076?source=related_link\">",
"      Patient information: Lung cancer risks, symptoms, and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/55/37749?source=related_link\">",
"      Photodynamic therapy of lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15400?source=related_link\">",
"      Preoperative evaluation for lung resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1830?source=related_link\">",
"      Prophylactic cranial irradiation for patients with small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/10/19625?source=related_link\">",
"      Role of imaging in the staging of non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38469?source=related_link\">",
"      Role of surgery in multimodality therapy for small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/35/44601?source=related_link\">",
"      Treatment of brain metastases in favorable prognosis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/21/44373?source=related_link\">",
"      Tumor node metastasis (TNM) staging system for non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/53/10072?source=related_link\">",
"      Women and lung cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13274="Maternal endocrine and metabolic adaptation to pregnancy";
var content_f12_61_13274=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Maternal endocrine and metabolic adaptation to pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Felice Petraglia, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Donato D'Antona, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/61/13274/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/61/13274/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pregnant woman undergoes profound anatomic and physiologic changes in almost every organ system. These adaptations to the pregnant state begin just after conception and evolve through delivery, after which they almost completely revert back to the nonpregnant state over a period of weeks. The purpose of these alterations is to accommodate the needs of the maternal-fetal unit.",
"   </p>",
"   <p>",
"    The normal metabolic and endocrinologic changes in pregnancy will be reviewed here. Metabolic and endocrinologic diseases complicating pregnancy are discussed separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOCRINE ADAPTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal endocrine adaptations to pregnancy involve the hypothalamus, pituitary, parathyroid, thyroid, adrenal glands, and ovary, and are linked to the interactions of the fetal-placental-maternal unit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypothalamic hormones",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypothalamus regulates much of the endocrine system by coordinating input from multiple areas and output via the hypothalamic-pituitary axis through cell to cell communication (paracrine signaling) and within the same cell communication (autocrine signaling). This axis directly affects the function of the thyroid gland, the adrenal gland, and the gonads and influences growth, lactation, and water balance (",
"    <a class=\"graphic graphic_table graphicRef53814 \" href=\"UTD.htm?6/3/6204\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An intact hypothalamus is necessary for natural conception; however, it is not essential when assisted reproductive techniques are being employed as long as full hormone replacement therapy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=see_link\">",
"     \"Hypothalamic-pituitary axis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The hypothalamic stimulatory hormones are gonadotropin-releasing hormone (GnRH), corticotropin-releasing hormone (CRH), growth hormone-releasing hormone (GHRH), thyrotropin-releasing hormone (TRH), and prolactin-releasing factors. Somatostatin and prolactin-inhibiting factors are inhibitory hypothalamic hormones. These hormones are present at high concentrations in the portal circulation where they are biologically active, but are almost nondetectable in the systemic circulation of nonpregnant women. However, the circulating concentrations of many of these hormones rise during pregnancy due to placental production of identical or variant hormones.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GnRH is a decapeptide hormone that mediates reproductive function via the hypothalamic-pituitary-gonadal axis [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/4\">",
"       4",
"      </a>",
"      ]. GnRH concentration increases during pregnancy, but the physiological significance of this change has not been determined [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The main source of circulating GnRH is the placenta where it may play a role in placental growth and function [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/7\">",
"       7",
"      </a>",
"      ]. Placental GnRH concentration increases until the second trimester and then plateaus [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/8\">",
"       8",
"      </a>",
"      ], whereas GnRH mRNA expression remains stable throughout the pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CRH is a 41 amino acid peptide involved in the response to stress [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/10\">",
"       10",
"      </a>",
"      ]. It is directed at the corticotroph cells of the pituitary, thereby regulating ACTH secretion during stressful events. CRH is expressed by placental and chorionic trophoblasts, amnion, and decidual cells [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/11-15\">",
"       11-15",
"      </a>",
"      ]. Its concentration in maternal circulation is high and rises exponentially throughout pregnancy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/5\">",
"       5",
"      </a>",
"      ]; CRH mRNA expression also increases during gestation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      In the placental HPA axis, cortisol stimulates CRH release in the decidua-trophoblast-membranes compartment [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/13\">",
"       13",
"      </a>",
"      ]. Placental CRH, in turn, appears to further drive maternal and fetal pituitary activation, establishing a potent positive feedback loop. The rise in CRH, either at term or preterm, has been suggested as a link to the initiation of labor [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/16-18\">",
"       16-18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Besides the secretion of CRH, gestational tissues are also able to secrete urocortin [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/19\">",
"       19",
"      </a>",
"      ], a member of the CRH family, which has a 45 percent homology with CRH and shares the same functions. Two additional members of the CRH family, urocortin 2 and 3, have been characterized in gestational tissue and have a role in the control of vascular endothelial tone. They have structural homology (34 and 32 percent, respectively) with CRH, but neither is able to stimulate ACTH secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=see_link\">",
"       \"Pathogenesis of spontaneous preterm birth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Growth hormone releasing hormone is a 44 amino acid peptide. Its concentration throughout pregnancy is similar to that in nonpregnant women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/21\">",
"       21",
"      </a>",
"      ]. However, growth hormone (GH) values are higher during pregnancy due to placental secretion of a variant of this hormone (vGH) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/22,23\">",
"       22,23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Somatostatin is a neuropeptide and is also produced by the placenta; the amount of hormone secreted decreases with advancing gestation. Placental somatostatin appears to inhibit production of human chorionic somatomammotropin (hCS), a hormone that causes insulin resistance. Thus, reduced secretion of somatostatin in the latter half of pregnancy may represent a factor in the insulin resistance observed at that time (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Glucose metabolism'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      TRH does not increase in the systemic circulation. Placental synthesis of immunologically active TRH occurs, but at a low level [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/24\">",
"       24",
"      </a>",
"      ]. Exogenously administered TRH crosses the placenta and can stimulate the fetal pituitary [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Kisspeptin is a neuropeptide product of the tumor suppressor gene, KISS-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/26\">",
"       26",
"      </a>",
"      ]. One of its functions is central control of the gonadotropic axis, particularly the pubertal process [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/27,28\">",
"       27,28",
"      </a>",
"      ]. This effect is likely mediated via release of GnRH. Reproductive dysfunction associated with leptin-deficient states may be related to diminished expression of KISS-1. Kisspeptin is also produced by the placenta and appears to play a role in placentation (trophoblast invasion) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. It is produced by syncytiotrophoblast and serum levels markedly increase in pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Pituitary gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior lobe of the pituitary gland enlarges up to threefold during gestation because of hyperplasia and hypertrophy of lactotrophs (",
"    <a class=\"graphic graphic_figure graphicRef73519 \" href=\"UTD.htm?22/29/23005\">",
"     figure 1",
"    </a>",
"    ). These changes do not completely resolve in the postpartum period; however, magnetic resonance imaging of the pituitary demonstrates a return to normal volume within six months after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Anterior pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is associated with a variety of changes in hormone release from the anterior pituitary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is a decline in circulating gonadotropin concentrations across gestation with a progressively diminishing response to GnRH. The suppression of gonadotropins is probably due to the high estradiol and progesterone concentrations during pregnancy. This is also probably due to the effect of the high maternal serum levels of inhibin A and inhibin B produced by placenta and fetal membranes throughout the pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=see_link\">",
"       \"Physiology of gonadotropin-releasing hormone\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhibins and activins'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Growth hormone production is reduced. Pituitary GH exhibits a decline by 24 weeks of gestation and is replaced by rising placental-derived GH, which peaks at 35 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/21,33\">",
"       21,33",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=see_link\">",
"       \"Physiology of growth hormone\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an increase in serum adrenocorticotropic hormone (ACTH) concentrations [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/34\">",
"       34",
"      </a>",
"      ], probably in response to CRH produced by trophoblasts which, as noted above, are stimulated by cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/13\">",
"       13",
"      </a>",
"      ]. The increase in ACTH is associated with increases in serum, salivary, and urinary free cortisol [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/35\">",
"       35",
"      </a>",
"      ]. Thus, pregnancy is a state of relative hypercortisolism [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thyrotropin (TSH) secretion is modestly reduced in the first trimester in response to the thyrotropic effects of rising human chorionic gonadotropin levels [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/36\">",
"       36",
"      </a>",
"      ]. In contrast, serum TSH concentrations may be modestly elevated at term due to increases in renal iodine clearance and placental degradation of thyroid hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/36,37\">",
"       36,37",
"      </a>",
"      ]. During pregnancy TSH retains its normal circadian rhythm (nocturnal surge), indicating an intact pituitary-thyroid axis.",
"     </li>",
"     <li>",
"      The serum prolactin concentration (PRL) increases throughout pregnancy, reaching a peak at delivery to prepare the breast for lactation (",
"      <a class=\"graphic graphic_figure graphicRef82454 \" href=\"UTD.htm?5/46/5869\">",
"       figure 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/38\">",
"       38",
"      </a>",
"      ]. The magnitude of the increase is quite variable; in one study, as an example, the mean value at term was 207",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      with a range of 35 to 600",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/38\">",
"       38",
"      </a>",
"      ]. The probable cause of hyperprolactinemia is the increasing serum estradiol concentration during pregnancy. By six weeks after delivery, estradiol secretion has decreased and the basal serum prolactin concentration is usually normal in the non-breast feeding mother. In women who are nursing, the decline in serum prolactin level is slower and marked by intermittent hyperprolactinemia related to suckling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Pregnancy appears to permanently reduce pituitary prolactin secretion. This was illustrated in a study that compared basal and stimulated prolactin levels in 24 women before and after a first full-term pregnancy to 40 nulliparous controls [",
"      <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/39\">",
"       39",
"      </a>",
"      ]. The serum prolactin concentration was lower in parous women at up to 12 years postpartum.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Intermediate lobe of the pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intermediate lobe of the pituitary increases in volume during pregnancy. This increase is correlated with higher melanocyte-stimulating hormone (MSH) levels, which increase beginning in the first trimester. The placenta is probably not a source of alpha-melanotrophin, but the fetus is a possible source [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/40\">",
"     40",
"    </a>",
"    ]. Hyperpigmentation (linea nigra, chloasma), normally present in most pregnant women, is linked to the increased MSH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Posterior pituitary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The posterior lobe of the pituitary gland is a storage terminal for oxytocin and antidiuretic hormone (ADH, arginine vasopressin), produced by the supraoptic and paraventricular hypothalamic nuclei. Antidiuretic hormone plays a major role in controlling plasma osmolality, which is primarily determined by the plasma sodium concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The plasma sodium concentration falls approximately 5",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    early in pregnancy due to resetting of the osmoreceptors for ADH release and thirst [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/42\">",
"     42",
"    </a>",
"    ]. This effect appears to be mediated by the increase in human chorionic gonadotropin&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/43\">",
"     43",
"    </a>",
"    ]. Another change is that the metabolic clearance rate of ADH markedly increases between gestational week 10 and midpregnancy due to vasopressinase released by the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/44\">",
"     44",
"    </a>",
"    ]. The plasma ADH concentration usually remains normal in pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/45\">",
"     45",
"    </a>",
"    ], but some women develop polyuria due to transient diabetes insipidus. At least some of these women may have reduced secretory reserve of ADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=see_link&amp;anchor=H22#H22\">",
"     \"Renal and urinary tract physiology in normal pregnancy\", section on 'Polyuria and diabetes insipidus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxytocin is involved in the process of parturition and the \"let down\" response during lactation. Maternal plasma concentrations rise continuously across gestation, with no further increase around the onset of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/46\">",
"     46",
"    </a>",
"    ]. Postpartum, nipple stimulation promotes the release of oxytocin. Milk ejection ensues due to stimulation of myoepithelial cells in ductal smooth muscle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Parathyroid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal calcium homeostasis during pregnancy adapts to meet the calcium demands of the fetus, which is 200 mg daily in the third trimester and with a total calcium accumulation of 30 grams. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=see_link\">",
"     \"Calcium physiology in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thyroid gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The maternal thyroid gland undergoes a number of physiologic modifications to meet the metabolic demands of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. An increase in thyroxine-binding globulin (TBG) occurs and, as noted above, TSH secretion is modestly reduced in the first trimester in response to the thyrotropic effects of rising human chorionic gonadotropin concentrations, and may be modestly increased at term.",
"   </p>",
"   <p>",
"    The size of the thyroid gland remains normal during pregnancy; thus, the presence of a goiter should always be investigated. A meta-analysis of all available studies of thyroid size and function in pregnancy found that thyroid size, estimated by inspection and palpation or measured by ultrasonography, increased only in areas of iodine deficiency, and the increase in average glandular size remained within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Controlled ovarian hyperstimulation with exogenous gonadotropins (for in vitro fertilization) results in a rise in serum TBG, T4, and T3 concentrations, a fall in serum free T4 concentration, and a small rise in serum TSH concentrations (usually within the normal range) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The serum TBG concentration rises twofold during pregnancy because estrogen both increases TBG production and sialylation; the latter reduces the clearance of TBG [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. TBG excess leads to an increase in both serum total thyroxine (T4) and triiodothyronine (T3) concentrations, but not the physiologically important serum free T4 and T3 concentrations (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=see_link\">",
"     \"Euthyroid hyperthyroxinemia and hypothyroxinemia\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Issues related to thyroid function and dysfunction during pregnancy are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=see_link\">",
"     \"Hyperthyroidism during pregnancy: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=see_link\">",
"     \"Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link&amp;anchor=H15#H15\">",
"     \"Subclinical hyperthyroidism\", section on 'Pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adrenal gland",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adrenal glands do not undergo morphologic changes during pregnancy. Adrenal steroidogenesis leads to the production of three types of steroids: mineralocorticoids are synthesized in the zona glomerulosa; glucocorticoids are produced in the zona fasciculata; and sex steroids come from the zona reticularis (",
"    <a class=\"graphic graphic_figure graphicRef70372 \" href=\"UTD.htm?0/7/123\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=see_link\">",
"     \"Adrenal steroid biosynthesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The renin-angiotensin system is the primary determinant of adrenal aldosterone secretion, although ACTH and hyperkalemia also play a role. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .) The renin-angiotensin-aldosterone system is stimulated during pregnancy because of the associated reductions in vascular resistance and blood pressure and the progressive decline in vascular responsiveness to angiotensin II [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. A striking increase in aldosterone levels is observed by the eighth week of pregnancy and continues to rise to 80 to 100",
"    <span class=\"nowrap\">",
"     ng/dl",
"    </span>",
"    in the third trimester, four- to six-fold above the upper limits observed in euvolemic nonpregnant adults. The blood pressure is usually 10 mmHg below baseline in the second trimester, declining to a mean of",
"    <span class=\"nowrap\">",
"     105/60",
"    </span>",
"    mmHg. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum concentrations of progesterone (produced by the placenta), which competes with aldosterone for binding to the mineralocorticoid receptor and therefore has a natriuretic effect, are increased throughout pregnancy, reaching a level of 200",
"    <span class=\"nowrap\">",
"     ng/dl",
"    </span>",
"    by term [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/55\">",
"     55",
"    </a>",
"    ]. Special interest has been directed towards progesterone because the concentration changes parallel that of aldosterone. Some investigators have postulated that high plasma levels of aldosterone during pregnancy reflect a compensatory response to salt-losing factors, such as progesterone, and the increased filtration of extracellular fluid by the kidney. Numerous studies however, indicate that the action of aldosterone can be separated from that of progesterone. As an example, when sodium balance is perturbed by decreases or increases in dietary sodium there are immediate and appropriate changes in plasma aldosterone levels. At high sodium levels, the aldosterone level falls to values observed in euvolemic pregnant adults, in the present of high stable plasma levels of progesterone. Therefore, it seems likely that aldosterone is critical in maintaining sodium balance in the setting of dilatation of the peripheral vasculature. This proposal has been strengthened by studies in the rat model of pregnancy, as a result of the direct action of a vasodilating factor called relaxin. This peptide hormone belongs to the insulin family and reproduces the vascular changes that characterize human pregnancy when administered to male animals and castrated females. Relaxin is normally produced in the corpus luteum, but in pregnancy is produced in large amounts by this placenta and decidua during pregnancy.",
"   </p>",
"   <p>",
"    Other humoral factors also contribute to volume regulation during pregnancy. The circulating concentration of atrial natriuretic peptide reaches its nadir late in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/56\">",
"     56",
"    </a>",
"    ], when plasma renin activity and serum aldosterone concentrations reach their peak [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/54\">",
"     54",
"    </a>",
"    ]. These observations are consistent with a state of effective hypovolemia that is presumably due to the fall in blood pressure.",
"   </p>",
"   <p>",
"    While cortisol is formally under the control of the HPA axis, as noted above, placental CRH increases progressively during the second and third trimester, driving increases in maternal ACTH and free cortisol throughout gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/57\">",
"     57",
"    </a>",
"    ]. Cortisol-binding globulin increases two- to three-fold during pregnancy so that the total circulating cortisol is increased to a greater degree than the free cortisol concentration.",
"   </p>",
"   <p>",
"    Similarly, serum total testosterone concentrations rise in pregnancy because of a sixfold increase in sex hormone-binding globulin. The free testosterone concentration is comparable to the nonpregnant state before the 28th gestational week, but exceeds normal nonpregnant levels in the third trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/58\">",
"     58",
"    </a>",
"    ]. The androstenedione concentration also increases in the third trimester, while the dehydroepiandrosterone sulfate level falls (despite increased fetal production) because of increased metabolic clearance rate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35798?source=see_link\">",
"     \"Androgen production and metabolism in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inhibins and activins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibins and activins are members of the transforming growth factor beta (TGFb) superfamily, a group of structurally similar, but functionally diverse growth factors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/59\">",
"     59",
"    </a>",
"    ]. The decidua, membranes, and fetus all produce inhibins and activins; however, the placenta is the major source [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. Measurement of these TGFs has several potential clinical applications, but the only such application demonstrated to be useful is as part of a Down syndrome screening program [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"     \"Second trimester maternal serum screening for Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibin is a heterodimer composed of alpha and beta subunits linked by a disulphide bridge. It exists in two forms, inhibin A and inhibin B, because the beta subunit can exist in two forms. During pregnancy only inhibin A shows significant changes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/64\">",
"     64",
"    </a>",
"    ]. The corpus luteum contributes to elevation of inhibin A levels in the first trimester, but the placenta is the main source of secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/65\">",
"     65",
"    </a>",
"    ]. In pregnant women, inhibin concentrations are elevated at five weeks of gestation, rise to a peak at 8 to 10 weeks, decrease during the second trimester, and rise again in the third trimester reaching a 48-fold increase near term [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/66\">",
"     66",
"    </a>",
"    ]. Measurement of inhibin levels has been investigated for early detection of pregnancy loss, ectopic pregnancy, preterm labor, and preeclampsia; singleton versus multiple pregnancy following in vitro fertilization-embryo transfer or ovulation induction protocols; and as a fourth marker in maternal screening for Down syndrome screening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activin A is a homodimer composed of two inhibin A beta subunits. Levels of activin A do not vary significantly during the first and second trimesters, although they are higher than during the menstrual cycle. After 24 weeks, activin A levels rise reaching a 22-fold increase at term [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. A possible role of activin A in parturition and fetal hypoxic stress is under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Activin A has been identified as a possible marker for ectopic pregnancy; levels are significantly lower than in spontaneous abortions and viable pregnancies of 100 percent and specificity of 99.6 percent have been reposted [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/75\">",
"     75",
"    </a>",
"    ]. A possible role of activin A in parturition and fetal hypoxic stress has also been suggested [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Umbilical cord activin A levels were elevated in preterm infants who developed perinatal intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/76\">",
"     76",
"    </a>",
"    ], and in the cerebral spinal fluid of term infants with hypoxic ischemic encephalopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/77\">",
"     77",
"    </a>",
"    ], and in the urine of asphyxiated newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The biological function of activin is mediated by follistatin, a monomeric glycoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/79\">",
"     79",
"    </a>",
"    ] which prevents activin binding to its receptors. Follistatin-related gene (FLRG) protein is made up of 70 amino acids. Its modular architecture is remarkably similar to that of follistatin and its primary sequence is homologous [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/80\">",
"     80",
"    </a>",
"    ]. Like follistatin, FLRG also interacts physically with activin-A, regulating its functions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urocortins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urocortins are members of the CRF peptide family and are expressed by reproductive tissues. Synthetic human urocortin is bound with high affinity to CRF receptors, and, in vitro, acts to release ACTH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urocortin may affect the physiology of human reproduction through",
"    <span class=\"nowrap\">",
"     paracrine/autocrine",
"    </span>",
"    actions. In vitro data show that urocortin 1 stimulates the secretion of ACTH, prostaglandins, and activin A from cultured human placental cells, and regulates placental vessel resistance to blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/83\">",
"     83",
"    </a>",
"    ]. When incubated with myometrial strips, urocortin stimulates uterine contractility by activating specific intracellular pathways. These findings suggest that urocortin plays a role in the human physiology of pregnancy and parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/84\">",
"     84",
"    </a>",
"    ]. Homologies with CRF were further demonstrated by the observation that both CRF and urocortin bind to the CRF-binding protein. Taken together, these findings support the conclusion that urocortins are members of the CRF peptide family and that they can mimic CRF activity.",
"   </p>",
"   <p>",
"    Evidence that urocortin in maternal circulation is mainly derived from fetal sources [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/85\">",
"     85",
"    </a>",
"    ] raises questions as to the role played by the interaction between the fetus and the maternal environment in maintaining uterine quiescence, as well as in the onset and maintenance of term and preterm parturition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/84\">",
"     84",
"    </a>",
"    ]. High urocortin levels in maternal serum are associated with both term and preterm delivery. Maternal plasma urocortin concentrations are significantly higher in women who deliver preterm than in those who progress to term. Furthermore, in patients who experience preterm delivery, urocortin concentrations are negatively correlated to the delivery time interval and are significantly higher in those delivering earlier in gestation. For prediction of preterm delivery in women with threatened preterm labor, a urocortin threshold of 113.9",
"    <span class=\"nowrap\">",
"     pg/ml",
"    </span>",
"    achieved a sensitivity of 80 percent and a specificity of 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Urocortin receptors have been found on endothelial and smooth muscle cells, and their activation modulates peripheral vascular resistance by endothelium-dependent (activation of nitric oxide pathway) and endothelium-independent (direct stimulation of vascular smooth muscle relaxation) mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/86\">",
"     86",
"    </a>",
"    ]. Urocortin concentrations correlate with hemodynamic changes of the blood flow from the mother to the fetus through the placenta, leading to the hypothesis that urocortin may be released in high amounts from fetal sources in the maternal circulation to reduce maternal vascular resistance and to increase the perfusion of the placenta. Thus, it may represent an adaptive fetal response to maternal hypertensive disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two additional members of the CRF family have been discovered: urocortin 2 (also known as stresscopin-related peptide) and urocortin 3 (also known as stresscopin), which mediate stress coping responses during the recovery phase of stress. Human placenta, decidua, and fetal membranes express urocortin 2 and urocortin 3, but despite their homology to CRF, they do not stimulate placental ACTH secretion. They may have a role in regulating placental vascular endothelial tone (",
"    <a class=\"graphic graphic_figure graphicRef83570 \" href=\"UTD.htm?24/62/25574\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     METABOLIC ADAPTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal physiology during pregnancy, especially late in gestation, is primarily influenced by placental hormones. These hormones affect both glucose and lipid metabolism to ensure that the fetus has an ample supply of fuel and nutrients at all times [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In addition, a small part of the physiological maternal weight gain is based on metabolic alterations leading to deposition of fat, protein, and water in the intracellular component. Nutritional requirements in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These changes are most important in late pregnancy when there is increased fetal growth and, therefore, demand for nutrients. The maternal response is characterized by a switch from carbohydrate to fat utilization that is facilitated by both insulin resistance and increased plasma concentrations of lipolytic hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/88\">",
"     88",
"    </a>",
"    ]. These adaptations are associated with large fluctuations in glucose and insulin as the mother oscillates between the fed and fasted states. The fasted state is one of \"accelerated starvation\" in which alternative fuels are made available to the mother, while glucose is reserved for the fetus. After an overnight fast, as an example, the maternal fasting capillary whole blood glucose concentration falls [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/88\">",
"     88",
"    </a>",
"    ], while plasma ketone and free fatty acid concentrations rise [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Glucose metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbohydrate metabolism in the later part of pregnancy is directed toward supplying glucose and amino acids to the growing fetus, while providing extra free fatty acids, ketones, and glycerol as sources of maternal fuel. Normal pregnancy is characterized by hyperplasia of the insulin-secreting pancreatic beta cells, increased insulin secretion, and an early increase in insulin sensitivity followed by progressive insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/88\">",
"     88",
"    </a>",
"    ]. Insulin and insulin-like growth factors are essential for the regulation of energy metabolism, cell proliferation, tissue development, and differentiation.",
"   </p>",
"   <p>",
"    The lactogenic hormones prolactin and chorionic somatomammotropin (hCS; also called human placental lactogen) cause an increase in the number of pancreatic beta cells in pregnancy. The mechanism regulating hyperplasia of the insulin-secreting pancreatic beta cells during pregnancy is not well defined. A study in mice showed that lactogenic hormone signaling via the prolactin receptor controls the rate limiting step in serotonin synthesis and that serotonin signaling drives the adaptive expansion of the beta cell mass [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/90\">",
"     90",
"    </a>",
"    ]. Another study in mice reported that menin (protein product of the MEN1 gene) was suppressed in normal pregnancy, possibly due to increasing prolactin levels, and that pancreatic islet cell growth was stimulated in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/91\">",
"     91",
"    </a>",
"    ]. Conversely, expression of menin prevented hyperplasia of the insulin-secreting pancreatic beta cells and resulted in gestational diabetes. Fox M1, a transcription factor in beta cell replication, is also required for prolactin induced beta cell expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/92\">",
"     92",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Insulin levels are higher both in the fasting and postprandial states. By comparison, fasting glucose concentrations are 10 to 20 percent lower during pregnancy due to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased storage of tissue glycogen",
"     </li>",
"     <li>",
"      Increased peripheral glucose utilization",
"     </li>",
"     <li>",
"      Decreased hepatic glucose production",
"     </li>",
"     <li>",
"      Glucose consumption by the fetus (especially in late pregnancy)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal insulin resistance results from increased placental secretion of diabetogenic hormones including growth hormone, CRH (which drives the release of ACTH and cortisol), hCS, and progesterone. In addition to the direct hyperglycemic effects of some of these hormones, a postreceptor defect also may contribute to the decline in insulin action [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], but the molecular mechanisms by which placental hormones alter insulin sensitivity are not well-characterized.",
"   </p>",
"   <p>",
"    Maternal glucose homeostasis shows important differences from the nonpregnant state, such as transient maternal hyperglycemia after meals due to increasing insulin resistance and transient hypoglycemia between meals and at night due to the continuous fetal draw [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/88\">",
"     88",
"    </a>",
"    ]. A 2011 literature review of studies describing the normal 24 hour glycemic profile of pregnant women comprised only 12 studies including a total of 255 nondiabetic subjects, mostly nonobese and mostly in the late third trimester of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/95\">",
"     95",
"    </a>",
"    ]. The pooled weighted mean glucose values (&plusmn; 1 SD) were fasting 71 &plusmn; 8",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    one hour postprandial 109 &plusmn; 13",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    two hour postprandial 99 &plusmn; 10",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and 24-hour glucose 88 &plusmn; 10",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"   </p>",
"   <p>",
"    Insulin resistance and the relative hypoglycemia of pregnant women results in increased lipolysis, which allows the mother to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preferentially use fat (eg, free fatty acids, triglycerides, ketone bodies) for fuel",
"     </li>",
"     <li>",
"      Preserve much of the available glucose and amino acids (especially alanine) for the fetus",
"     </li>",
"     <li>",
"      Minimize protein catabolism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The placenta readily transfers glucose, amino acids, and ketone bodies to the fetus, but is impermeable to large lipids. Thus, the placenta affects maternal-fetal fuel metabolism in two important ways: by the production of placental hormones that alter maternal carbohydrate and lipid metabolism; and by controlling transplacental passage of glucose, fat, and protein.",
"   </p>",
"   <p>",
"    The insulin resistance of pregnancy also becomes important in certain disease states. Gestational diabetes mellitus occurs when a woman's pancreatic function is not sufficient to overcome the insulin resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .) On the other hand, the pregnancy-associated insulin resistance rapidly decreases during labor, since expulsion of the fetoplacental unit leads to cessation of production of somatomammotropin, which has a short half-life. This has important implications for the woman with type 1 diabetes in whom insulin requirements fall to zero during labor and delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=see_link\">",
"     \"Medical management of type 1 and type 2 diabetes mellitus in pregnant women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Lipid metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Until recently, the adipose tissue has been considered a reservoir to store calories. Actually, the white adipose tissue is a very active endocrine organ, which also releases a number of endocrine and paracrine factors termed adipokines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum total cholesterol and triglyceride concentrations increase markedly during pregnancy (",
"    <a class=\"graphic graphic_table graphicRef59609 \" href=\"UTD.htm?21/22/21867\">",
"     table 2",
"    </a>",
"    ), but reported ranges vary among studies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=see_link&amp;anchor=H11#H11\">",
"     \"Maternal gastrointestinal tract adaptation to pregnancy\", section on 'Liver'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The large rise in triglycerides appears to be due to two factors: increased hepatic lipase activity, leading to enhanced hepatic triglyceride synthesis, and reduced lipoprotein lipase activity, resulting in decreased catabolism of adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link\">",
"     \"Approach to the patient with hypertriglyceridemia\"",
"    </a>",
"    .) Apolipoproteins A-I, A-II, and B also rise across gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/97\">",
"     97",
"    </a>",
"    ], while HDL-cholesterol concentrations initially increase and then fall in the third trimester.",
"   </p>",
"   <p>",
"    These changes in lipid metabolism are adaptive to fetal-maternal needs: high triglyceride concentrations provide maternal fuel while sparing glucose for the fetus; and placental steroidogenesis is aided by elevated LDL cholesterol levels. In particular, fat accumulation characterizes the second trimester, while the third trimester is characterized by maternal consumption of the stored fat. How they occur is not completely understood, but the above changes in the hormones affecting glucose and lipid metabolism (eg, insulin, cortisol) and in sex hormones are thought to be important.",
"   </p>",
"   <p>",
"    It is not known whether the elevated lipoprotein concentrations during normal pregnancy are related to atherosclerosis later in life. Studies attempting to correlate the risk of coronary heart disease and number of pregnancies have produced contradictory results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leptin and adiponectin are members of the family of adipokines: proteins secreted by the adipose tissue. Adipokines have an important role in the metabolism, inflammation, cardiovascular and endocrine system, mediating crosstalk between insulin-sensitive tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/102,103\">",
"     102,103",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leptin is a hormone secreted by adipose tissue and by the placenta that has a key role in fat metabolism. In pregnancy there is a significant increase in its level in maternal serum, peaking in the second trimester and remaining elevated until delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/104\">",
"     104",
"    </a>",
"    ]. Leptin levels have been linked to pregnancy-specific pathologies such as gestational diabetes, preeclampsia, and intrauterine growth restriction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/105,106\">",
"     105,106",
"    </a>",
"    ]. However, the functions of leptin in pregnant women, the fetus, and the placenta have not been determined; many observations suggest leptin is able to modulate insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/107-109\">",
"     107-109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adiponectin is a protein produced by the maternal and fetal adipose tissue and plays a role in the modulation of glucose and lipid metabolism in insulin-sensitive tissues and the developing of gestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/109\">",
"     109",
"    </a>",
"    ]. Adiponectin cord blood levels are significantly higher than maternal levels, with no correlations between the two compartments [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/110\">",
"     110",
"    </a>",
"    ]. The maternal adiponectin levels decrease during pregnancy; and, in the third trimester, adiponectin concentrations are lower than in the pregravid condition [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Protein metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Significant augmentation of protein intake is important in pregnancy to fulfill the needs of the growing fetus, the placenta, and maternal changes, such as the enlarging uterus and breasts and increased volume of blood components [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/111\">",
"     111",
"    </a>",
"    ]. The Recommended Dietary Allowance (RDA) for protein during pregnancy is based on estimates of the efficiency of protein utilization in pregnant women. It is recommended that pregnant women consume 60 grams of protein per day, which is only 10 grams more than in nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=see_link\">",
"     \"Nutrition in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Water metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Water retention is a physiological phenomenon in pregnancy, with an average increase at term of 3 liters. Water retention is clinically evident as edema of the ankles and legs, a normal finding in a large proportion of pregnant women near term.",
"   </p>",
"   <p>",
"    A fall in plasma osmolality of 10",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    is one of the main reasons for water retention. Antidiuretic hormone release and the osmotic threshold for thirst decrease in parallel resulting in water retention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/61/13274/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endocrine adaptations to the pregnant state begin just after conception and evolve through delivery, after which they almost completely revert back to the nonpregnant state over a period of weeks. Pituitary, adrenal and pancreas are glands not frequently affected by pregnancy, while thyroid dysfunction (hypothyroidism and hyperthyroidism) may result as a permanent condition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Endocrine adaptations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Maternal physiology during pregnancy is significantly affected by placental hormones, which affect glucose and lipid metabolism to ensure that the fetus has an ample supply of fuel and nutrients at all times. An excessive increase of maternal body mass index (BMI) during pregnancy, however, is a risk factor for development of obstetric syndromes (gestational diabetes mellitus, preeclampsia, preterm birth), and jeopardizes the woman&rsquo;s future health. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Metabolic adaptations'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"       \"The impact of obesity on fertility and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/1\">",
"      Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/2\">",
"      Krieger DT. Brain peptides: what, where, and why? Science 1983; 222:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/3\">",
"      Volz J, Heinrich U, Volz-K&ouml;ster S. Conception and spontaneous delivery after total hypophysectomy. Fertil Steril 2002; 77:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/4\">",
"      Stojilkovic SS, Reinhart J, Catt KJ. Gonadotropin-releasing hormone receptors: structure and signal transduction pathways. Endocr Rev 1994; 15:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/5\">",
"      Petraglia F, Florio P, Nappi C, Genazzani AR. Peptide signaling in human placenta and membranes: autocrine, paracrine, and endocrine mechanisms. Endocr Rev 1996; 17:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/6\">",
"      Siler-Khodr TM, Khodr GS, Valenzuela G. Immunoreactive gonadotropin-releasing hormone level in maternal circulation throughout pregnancy. Am J Obstet Gynecol 1984; 150:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/7\">",
"      Petraglia F, Woodruff TK, Botticelli G, et al. Gonadotropin-releasing hormone, inhibin, and activin in human placenta: evidence for a common cellular localization. J Clin Endocrinol Metab 1992; 74:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/8\">",
"      Siler-Khodr TM, Khodr GS. Content of luteinizing hormone-releasing factor in the human placenta. Am J Obstet Gynecol 1978; 130:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/9\">",
"      Kelly AC, Rodgers A, Dong KW, et al. Gonadotropin-releasing hormone and chorionic gonadotropin gene expression in human placental development. DNA Cell Biol 1991; 10:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/10\">",
"      Bale TL, Vale WW. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 2004; 44:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/11\">",
"      Frim DM, Emanuel RL, Robinson BG, et al. Characterization and gestational regulation of corticotropin-releasing hormone messenger RNA in human placenta. J Clin Invest 1988; 82:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/12\">",
"      Petraglia F, Tabanelli S, Galassi MC, et al. Human decidua and in vitro decidualized endometrial stromal cells at term contain immunoreactive corticotropin-releasing factor (CRF) and CRF messenger ribonucleic acid. J Clin Endocrinol Metab 1992; 74:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/13\">",
"      Petraglia F, Potter E, Cameron VA, et al. Corticotropin-releasing factor-binding protein is produced by human placenta and intrauterine tissues. J Clin Endocrinol Metab 1993; 77:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/14\">",
"      Petraglia F, Sawchenko PE, Rivier J, Vale W. Evidence for local stimulation of ACTH secretion by corticotropin-releasing factor in human placenta. Nature 1987; 328:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/15\">",
"      Florio P, Franchini A, Reis FM, et al. Human placenta, chorion, amnion and decidua express different variants of corticotropin-releasing factor receptor messenger RNA. Placenta 2000; 21:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/16\">",
"      Majzoub JA, McGregor JA, Lockwood CJ, et al. A central theory of preterm and term labor: putative role for corticotropin-releasing hormone. Am J Obstet Gynecol 1999; 180:S232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/17\">",
"      Reis FM, Fadalti M, Florio P, Petraglia F. Putative role of placental corticotropin-releasing factor in the mechanisms of human parturition. J Soc Gynecol Investig 1999; 6:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/18\">",
"      Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/19\">",
"      Florio P, Vale W, Petraglia F. Urocortins in human reproduction. Peptides 2004; 25:1751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/20\">",
"      Imperatore A, Florio P, Torres PB, et al. Urocortin 2 and urocortin 3 are expressed by the human placenta, deciduas, and fetal membranes. Am J Obstet Gynecol 2006; 195:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/21\">",
"      Mazlan M, Spence-Jones C, Chard T, et al. Circulating levels of GH-releasing hormone and GH during human pregnancy. J Endocrinol 1990; 125:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/22\">",
"      Eriksson L, Frankenne F, Ed&egrave;n S, et al. Growth hormone 24-h serum profiles during pregnancy--lack of pulsatility for the secretion of the placental variant. Br J Obstet Gynaecol 1989; 96:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/23\">",
"      L&oslash;nberg U, Damm P, Andersson AM, et al. Increase in maternal placental growth hormone during pregnancy and disappearance during parturition in normal and growth hormone-deficient pregnancies. Am J Obstet Gynecol 2003; 188:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/24\">",
"      Bajoria R, Babawale M. Ontogeny of endogenous secretion of immunoreactive-thyrotropin releasing hormone by the human placenta. J Clin Endocrinol Metab 1998; 83:4148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/25\">",
"      Roti E, Gnudi A, Braverman LE, et al. Human cord blood concentrations of thyrotropin, thyroglobulin, and iodothyronines after maternal administration of thyrotropin-releasing hormone. J Clin Endocrinol Metab 1981; 53:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/26\">",
"      Lee JH, Miele ME, Hicks DJ, et al. KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. J Natl Cancer Inst 1996; 88:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/27\">",
"      Roseweir AK, Millar RP. The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 2009; 15:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/28\">",
"      Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. N Engl J Med 2003; 349:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/29\">",
"      Bilban M, Ghaffari-Tabrizi N, Hintermann E, et al. Kisspeptin-10, a KiSS-1/metastin-derived decapeptide, is a physiological invasion inhibitor of primary human trophoblasts. J Cell Sci 2004; 117:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/30\">",
"      Horikoshi Y, Matsumoto H, Takatsu Y, et al. Dramatic elevation of plasma metastin concentrations in human pregnancy: metastin as a novel placenta-derived hormone in humans. J Clin Endocrinol Metab 2003; 88:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/31\">",
"      Torricelli M, Galleri L, Voltolini C, et al. Changes of placental Kiss-1 mRNA expression and maternal/cord kisspeptin levels at preterm delivery. Reprod Sci 2008; 15:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/32\">",
"      Din&ccedil; H, Esen F, Demirci A, et al. Pituitary dimensions and volume measurements in pregnancy and post partum. MR assessment. Acta Radiol 1998; 39:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/33\">",
"      Mirlesse V, Frankenne F, Alsat E, et al. Placental growth hormone levels in normal pregnancy and in pregnancies with intrauterine growth retardation. Pediatr Res 1993; 34:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/34\">",
"      Mastorakos G, Ilias I. Maternal hypothalamic-pituitary-adrenal axis in pregnancy and the postpartum period. Postpartum-related disorders. Ann N Y Acad Sci 2000; 900:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/35\">",
"      Meulenberg PM, Hofman JA. Differences between concentrations of salivary cortisol and cortisone and of free cortisol and cortisone in plasma during pregnancy and postpartum. Clin Chem 1990; 36:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/36\">",
"      Glinoer D. What happens to the normal thyroid during pregnancy? Thyroid 1999; 9:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/37\">",
"      Brent GA. Maternal thyroid function: interpretation of thyroid function tests in pregnancy. Clin Obstet Gynecol 1997; 40:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/38\">",
"      Tyson JE, Hwang P, Guyda H, Friesen HG. Studies of prolactin secretion in human pregnancy. Am J Obstet Gynecol 1972; 113:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/39\">",
"      Musey VC, Collins DC, Musey PI, et al. Long-term effect of a first pregnancy on the secretion of prolactin. N Engl J Med 1987; 316:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/40\">",
"      Wilson JF. Levels of alpha-melanotrophin in the human fetal pituitary gland throughout gestation, in adult pituitary gland and in human placenta. Clin Endocrinol (Oxf) 1982; 17:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/41\">",
"      Vaughan Jones SA, Black MM. Pregnancy dermatoses. J Am Acad Dermatol 1999; 40:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/42\">",
"      Lindheimer MD, Barron WM, Davison JM. Osmotic and volume control of vasopressin release in pregnancy. Am J Kidney Dis 1991; 17:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/43\">",
"      Davison JM, Shiells EA, Philips PR, Lindheimer MD. Serial evaluation of vasopressin release and thirst in human pregnancy. Role of human chorionic gonadotrophin in the osmoregulatory changes of gestation. J Clin Invest 1988; 81:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/44\">",
"      Davison JM, Sheills EA, Philips PR, et al. Metabolic clearance of vasopressin and an analogue resistant to vasopressinase in human pregnancy. Am J Physiol 1993; 264:F348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/45\">",
"      DeVane GW. Vasopressin levels during pregnancy and labor. J Reprod Med 1985; 30:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/46\">",
"      Leake RD, Weitzman RE, Glatz TH, Fisher DA. Plasma oxytocin concentrations in men, nonpregnant women, and pregnant women before and during spontaneous labor. J Clin Endocrinol Metab 1981; 53:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/47\">",
"      Glinoer D, de Nayer P, Bourdoux P, et al. Regulation of maternal thyroid during pregnancy. J Clin Endocrinol Metab 1990; 71:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/48\">",
"      Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/49\">",
"      Berghout A, Wiersinga W. Thyroid size and thyroid function during pregnancy: an analysis. Eur J Endocrinol 1998; 138:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/50\">",
"      Muller AF, Verhoeff A, Mantel MJ, et al. Decrease of free thyroxine levels after controlled ovarian hyperstimulation. J Clin Endocrinol Metab 2000; 85:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/51\">",
"      Fantz CR, Dagogo-Jack S, Ladenson JH, Gronowski AM. Thyroid function during pregnancy. Clin Chem 1999; 45:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/52\">",
"      Ain KB, Mori Y, Refetoff S. Reduced clearance rate of thyroxine-binding globulin (TBG) with increased sialylation: a mechanism for estrogen-induced elevation of serum TBG concentration. J Clin Endocrinol Metab 1987; 65:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/53\">",
"      D&ouml;rr HG, Heller A, Versmold HT, et al. Longitudinal study of progestins, mineralocorticoids, and glucocorticoids throughout human pregnancy. J Clin Endocrinol Metab 1989; 68:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/54\">",
"      Elsheikh A, Creatsas G, Mastorakos G, et al. The renin-aldosterone system during normal and hypertensive pregnancy. Arch Gynecol Obstet 2001; 264:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/55\">",
"      Funder JW. Aldosterone action: fact, failure and the future. Clin Exp Pharmacol Physiol Suppl 1998; 25:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/56\">",
"      Thomsen JK, Fogh-Andersen N, Jaszczak P, Giese J. Atrial natriuretic peptide (ANP) decrease during normal pregnancy as related to hemodynamic changes and volume regulation. Acta Obstet Gynecol Scand 1993; 72:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/57\">",
"      Clerico A, Del Chicca MG, Ferdeghini M, et al. Progressively elevated levels of biologically active (free) cortisol during pregnancy by a direct radioimmunological assay of diffusible cortisol in an equilibrium dialysis system. J Endocrinol Invest 1980; 3:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/58\">",
"      Kerlan V, Nahoul K, Le Martelot MT, Bercovici JP. Longitudinal study of maternal plasma bioavailable testosterone and androstanediol glucuronide levels during pregnancy. Clin Endocrinol (Oxf) 1994; 40:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/59\">",
"      Chang H, Brown CW, Matzuk MM. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 2002; 23:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/60\">",
"      Qu J, Thomas K. Inhibin and activin production in human placenta. Endocr Rev 1995; 16:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/61\">",
"      Petraglia F, Sawchenko P, Lim AT, et al. Localization, secretion, and action of inhibin in human placenta. Science 1987; 237:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/62\">",
"      Minami S, Yamoto M, Nakano R. Immunohistochemical localization of inhibin/activin subunits in human placenta. Obstet Gynecol 1992; 80:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/63\">",
"      Reis FM, D'Antona D, Petraglia F. Predictive value of hormone measurements in maternal and fetal complications of pregnancy. Endocr Rev 2002; 23:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/64\">",
"      Florio P, Luisi S, Ciarmela P, et al. Inhibins and activins in pregnancy. Mol Cell Endocrinol 2004; 225:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/65\">",
"      Luisi S, Florio P, Reis FM, Petraglia F. Inhibins in female and male reproductive physiology: role in gametogenesis, conception, implantation and early pregnancy. Hum Reprod Update 2005; 11:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/66\">",
"      Muttukrishna S, George L, Fowler PA, et al. Measurement of serum concentrations of inhibin-A (alpha-beta A dimer) during human pregnancy. Clin Endocrinol (Oxf) 1995; 42:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/67\">",
"      Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/68\">",
"      D'Antona D, Wallace EM, Shearing C, et al. Inhibin A and pro-alpha C inhibin in Down syndrome and normal pregnancies. Prenat Diagn 1998; 18:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/69\">",
"      Florio P, Luisi S, D'Antona D, et al. Maternal serum inhibin A levels may predict pregnancy outcome in women with threatened abortion. Fertil Steril 2004; 81:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/70\">",
"      Lockwood GM, Ledger WL, Barlow DH, et al. Measurement of inhibin and activin in early human pregnancy: demonstration of fetoplacental origin and role in prediction of early-pregnancy outcome. Biol Reprod 1997; 57:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/71\">",
"      Florio P, Cobellis L, Luisi S, et al. Changes in inhibins and activin secretion in healthy and pathological pregnancies. Mol Cell Endocrinol 2001; 180:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/72\">",
"      Florio P, Benedetto C, Luisi S, et al. Activin A, inhibin A, inhibin B and parturition: changes of maternal and cord serum levels according to the mode of delivery. Br J Obstet Gynaecol 1999; 106:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/73\">",
"      Florio P, Reis FM, Pezzani I, et al. The addition of activin A and inhibin A measurement to uterine artery Doppler velocimetry to improve the early prediction of pre-eclampsia. Ultrasound Obstet Gynecol 2003; 21:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/74\">",
"      Florio P, Perrone S, Luisi S, et al. Activin a plasma levels at birth: an index of fetal hypoxia in preterm newborn. Pediatr Res 2003; 54:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/75\">",
"      Florio P, Severi FM, Bocchi C, et al. Single serum activin a testing to predict ectopic pregnancy. J Clin Endocrinol Metab 2007; 92:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/76\">",
"      Florio P, Perrone S, Luisi S, et al. Increased plasma concentrations of activin a predict intraventricular hemorrhage in preterm newborns. Clin Chem 2006; 52:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/77\">",
"      Florio P, Luisi S, Bruschettini M, et al. Cerebrospinal fluid activin a measurement in asphyxiated full-term newborns predicts hypoxic ischemic encephalopathy. Clin Chem 2004; 50:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/78\">",
"      Florio P, Luisi S, Moataza B, et al. High urinary concentrations of activin A in asphyxiated full-term newborns with moderate or severe hypoxic ischemic encephalopathy. Clin Chem 2007; 53:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/79\">",
"      Luisi S, Florio P, Reis FM, Petraglia F. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol 2001; 145:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/80\">",
"      Maguer-Satta V, Bartholin L, Jeanpierre S, et al. Expression of FLRG, a novel activin A ligand, is regulated by TGF-beta and during hematopoiesis [corrected]. Exp Hematol 2001; 29:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/81\">",
"      Ciarmela P, Florio P, Toti P, et al. Human placenta and fetal membranes express follistatin-related gene mRNA and protein. J Endocrinol Invest 2003; 26:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/82\">",
"      Donaldson CJ, Sutton SW, Perrin MH, et al. Cloning and characterization of human urocortin. Endocrinology 1996; 137:2167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/83\">",
"      Petraglia F, Florio P, Benedetto C, et al. Urocortin stimulates placental adrenocorticotropin and prostaglandin release and myometrial contractility in vitro. J Clin Endocrinol Metab 1999; 84:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/84\">",
"      Florio P, Linton EA, Torricelli M, et al. Prediction of preterm delivery based on maternal plasma urocortin. J Clin Endocrinol Metab 2007; 92:4734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/85\">",
"      Florio P, Torricelli M, Galleri L, et al. High fetal urocortin levels at term and preterm labor. J Clin Endocrinol Metab 2005; 90:5361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/86\">",
"      Simoncini T, Apa R, Reis FM, et al. Human umbilical vein endothelial cells: a new source and potential target for corticotropin-releasing factor. J Clin Endocrinol Metab 1999; 84:2802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/87\">",
"      Florio P, Torricelli M, De Falco G, et al. High maternal and fetal plasma urocortin levels in pregnancies complicated by hypertension. J Hypertens 2006; 24:1831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/88\">",
"      Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. Am J Clin Nutr 2000; 71:1256S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/89\">",
"      Homko CJ, Sivan E, Reece EA, Boden G. Fuel metabolism during pregnancy. Semin Reprod Endocrinol 1999; 17:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/90\">",
"      Kim H, Toyofuku Y, Lynn FC, et al. Serotonin regulates pancreatic beta cell mass during pregnancy. Nat Med 2010; 16:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/91\">",
"      Karnik SK, Chen H, McLean GW, et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 2007; 318:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/92\">",
"      Zhang H, Zhang J, Pope CF, et al. Gestational diabetes mellitus resulting from impaired beta-cell compensation in the absence of FoxM1, a novel downstream effector of placental lactogen. Diabetes 2010; 59:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/93\">",
"      Yamashita H, Shao J, Friedman JE. Physiologic and molecular alterations in carbohydrate metabolism during pregnancy and gestational diabetes mellitus. Clin Obstet Gynecol 2000; 43:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/94\">",
"      Catalano PM, Kirwan JP, Haugel-de Mouzon S, King J. Gestational diabetes and insulin resistance: role in short- and long-term implications for mother and fetus. J Nutr 2003; 133:1674S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/95\">",
"      Hernandez TL, Friedman JE, Van Pelt RE, Barbour LA. Patterns of glycemia in normal pregnancy: should the current therapeutic targets be challenged? Diabetes Care 2011; 34:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/96\">",
"      Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89:2548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/97\">",
"      Brizzi P, Tonolo G, Esposito F, et al. Lipoprotein metabolism during normal pregnancy. Am J Obstet Gynecol 1999; 181:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/98\">",
"      Wiznitzer A, Mayer A, Novack V, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. Am J Obstet Gynecol 2009; 201:482.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/99\">",
"      Piechota W, Staszewski A. Reference ranges of lipids and apolipoproteins in pregnancy. Eur J Obstet Gynecol Reprod Biol 1992; 45:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/100\">",
"      Herrera E. Metabolic adaptations in pregnancy and their implications for the availability of substrates to the fetus. Eur J Clin Nutr 2000; 54 Suppl 1:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/101\">",
"      Napoli C, Palinski W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur Heart J 2001; 22:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/102\">",
"      Fanciulli G, Delitala A, Delitala G. Growth hormone, menopause and ageing: no definite evidence for 'rejuvenation' with growth hormone. Hum Reprod Update 2009; 15:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/103\">",
"      Paulsen SK, Pedersen SB, Fisker S, Richelsen B. 11Beta-HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 2007; 15:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/104\">",
"      Hauguel-de Mouzon S, Lepercq J, Catalano P. The known and unknown of leptin in pregnancy. Am J Obstet Gynecol 2006; 194:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/105\">",
"      Henson MC, Castracane VD. Leptin in pregnancy: an update. Biol Reprod 2006; 74:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/106\">",
"      McIntyre HD, Chang AM, Callaway LK, et al. Hormonal and metabolic factors associated with variations in insulin sensitivity in human pregnancy. Diabetes Care 2010; 33:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/107\">",
"      Arner P. Insulin resistance in type 2 diabetes -- role of the adipokines. Curr Mol Med 2005; 5:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/108\">",
"      Lepercq J, Challier JC, Guerre-Millo M, et al. Prenatal leptin production: evidence that fetal adipose tissue produces leptin. J Clin Endocrinol Metab 2001; 86:2409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/109\">",
"      Zavalza-G&oacute;mez AB, Anaya-Prado R, Rinc&oacute;n-S&aacute;nchez AR, Mora-Mart&iacute;nez JM. Adipokines and insulin resistance during pregnancy. Diabetes Res Clin Pract 2008; 80:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/110\">",
"      Chan TF, Yuan SS, Chen HS, et al. Correlations between umbilical and maternal serum adiponectin levels and neonatal birthweights. Acta Obstet Gynecol Scand 2004; 83:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/111\">",
"      Jackson AA. Nutrients, growth, and the development of programmed metabolic function. Adv Exp Med Biol 2000; 478:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/61/13274/abstract/112\">",
"      Heenan AP, Wolfe LA, Davies GA, McGrath MJ. Effects of human pregnancy on fluid regulation responses to short-term exercise. J Appl Physiol 2003; 95:2321.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 451 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13274=[""].join("\n");
var outline_f12_61_13274=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOCRINE ADAPTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypothalamic hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Pituitary gland",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Anterior pituitary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Intermediate lobe of the pituitary",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Posterior pituitary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Parathyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thyroid gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adrenal gland",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inhibins and activins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urocortins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      METABOLIC ADAPTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Glucose metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Lipid metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Protein metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Water metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/451\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/451|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/29/23005\" title=\"figure 1\">",
"      Pregnancy and pituitary size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/46/5869\" title=\"figure 2\">",
"      Serum prolactin in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/7/123\" title=\"figure 3\">",
"      Adrenal steroid synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/62/25574\" title=\"figure 4\">",
"      Urocortins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/451|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/3/6204\" title=\"table 1\">",
"      Hypothalamic hormones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/22/21867\" title=\"table 2\">",
"      Pregnancy lipoprotein levels",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28391?source=related_link\">",
"      Adrenal steroid biosynthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/61/35798?source=related_link\">",
"      Androgen production and metabolism in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2584?source=related_link\">",
"      Calcium physiology in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/856?source=related_link\">",
"      Euthyroid hyperthyroxinemia and hypothyroxinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/36/12871?source=related_link\">",
"      Hyperthyroidism during pregnancy: Clinical manifestations, diagnosis, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/48/42760?source=related_link\">",
"      Hyperthyroidism during pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25059?source=related_link\">",
"      Hypothalamic-pituitary axis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/47/14073?source=related_link\">",
"      Hypothyroidism during pregnancy: Clinical manifestations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/60/9160?source=related_link\">",
"      Maternal gastrointestinal tract adaptation to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20794?source=related_link\">",
"      Medical management of type 1 and type 2 diabetes mellitus in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/44/28362?source=related_link\">",
"      Nutrition in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/40/32393?source=related_link\">",
"      Pathogenesis of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/27/32181?source=related_link\">",
"      Physiology of gonadotropin-releasing hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43030?source=related_link\">",
"      Physiology of growth hormone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=related_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_61_13275="Exclusions organ donation";
var content_f12_61_13275=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Exclusions for organ donation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Severe untreated systemic sepsis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acquired immunodeficiency syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active viral hepatitis B or C, cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viral encephalitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active extracranial malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of rare viral or prion protein illness,&nbsp;such as&nbsp;Creutzfeldt-Jakob disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recipients of cadaver human pituitary growth hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Undiagnosed acute or progressive neurological disorder with or without dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active West Nile virus or rabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Active disseminated tuberculosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical exclusion criteria are listed here. No assumptions about donor suitability should be made prior to consultation with the Organ Procurement Organization.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13275=[""].join("\n");
var outline_f12_61_13275=null;
var title_f12_61_13276="Classification of morphea";
var content_f12_61_13276=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of morphea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Morphea&nbsp;subtype",
"       </td>",
"       <td class=\"subtitle1\">",
"        Modifiers",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Circumscribed",
"        </strong>",
"       </td>",
"       <td>",
"        Superficial",
"       </td>",
"       <td>",
"        Single or multiple oval/round lesions limited to epidermis and dermis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep",
"       </td>",
"       <td>",
"        Single or multiple oval/round lesions involving subcutaneous tissue, fascia or muscle",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Linear",
"        </strong>",
"       </td>",
"       <td>",
"        Trunk/limbs",
"       </td>",
"       <td>",
"        Linear lesions involving possible primary site of involvement in subcutaneous tissue without involvement of skin, dermis, subcutaneous tissue, muscle or bone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Head",
"       </td>",
"       <td>",
"        En coup de sabre, progressive facial hemiatrophy, linear lesions of the face (may involve underlying bone)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Coalescent plaque",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &ge;4 plaques in at least 2 of 7 anatomic sites (head-neck, right/left upper extremity, right/left lower extremity, anterior/posterior trunk); isomorphic pattern: coalescent plaques inframammary fold, waistline, lower abdomen, proximal thighs; symmetric pattern: symmetric plaques circumferential around breasts, umbilicus, arms, and legs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Pansclerotic",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Circumferential involvement of majority of body surface area (sparing fingertips and toes), affecting skin, subcutaneous tissue, muscle or bone; no internal organ involvement",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Mixed",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Combination of any above subtype (eg, linear-circumscribed)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Laxer RM, Zulian FB. Localized scleroderma. Curr Opin Rheumatol 2006; 18:606. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13276=[""].join("\n");
var outline_f12_61_13276=null;
var title_f12_61_13277="Adherence improvement patients";
var content_f12_61_13277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57486%7EID%2F78917%7EID%2F68684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57486%7EID%2F78917%7EID%2F68684&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=17\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to improve adherence: patient and medication-related",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Inform patient regarding side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticipate and treat side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Simplify food requirements.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid adverse drug interactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If possible, reduce dose frequency and number of pills.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Negotiate a treatment plan that the patient understands and to which",
"he/she commits.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spend time and multiple encounters to educate and explain goals of",
"therapy and need for adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Establish readiness to take medication before writing first",
"prescription.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Recruit family and friends to support the treatment plan.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop concrete plan for specific regimen by considering meals",
"schedule, daily routines, and side effects.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide written schedule and pictures of medications, daily or weekly",
"pillboxes, alarm clocks, pagers, or other mechanical aids for adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop adherence support groups or add adherence concerns to agenda of",
"other support groups.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Develop link with local community-based organizations regarding",
"adherence combined with educational sessions and practical strategies.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider practice sessions using candy instead of pills.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Strategies to improve adherence: clinician and health team-related",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Establish trust.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serve as educator and information source with ongoing support and",
"monitoring.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide access between visits for questions or problems (eg, by",
"providing a pager number), including during vacations or conferences.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Monitor ongoing adherence; intensify management during periods of",
"suboptimal adherence (ie, more frequent visits, recruitment of family",
"or friends,",
"deployment of other team members, and referral for mental health or",
"chemical-dependency services).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use health team for all patients, including patients with special needs",
"(eg, use peer educators for adolescents or for injection-drug users).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider impact of new diagnoses on adherence (eg, depression, liver",
"disease, wasting, or recurrent chemical dependency) and include",
"adherence intervention in management.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use nurses, pharmacists, peer educators, volunteers, case managers,",
"drug counselors, clinician's assistants, nurse practitioners, and",
"research nurses to reinforce adherence messages.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Provide training to support team regarding antiretroviral therapy and",
"adherence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Add adherence interventions to job descriptions of support team",
"members; add continuity-of-care role to improve patient access.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Interventions to improve adherence",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Pharmacist-based adherence encounters and clinics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multidisciplinary adherence encounters at each visit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reminders, alarms, pagers, or timers on pillboxes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient education aids, including regimen pictures, calendars, or",
"stickers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clinician education aids (eg, medication guides, pictures, or calendars)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     file://aidsinfo.nih.gov.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13277=[""].join("\n");
var outline_f12_61_13277=null;
var title_f12_61_13278="Circadian pattern SCD II";
var content_f12_61_13278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80656&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Circadian pattern of cardiac arrest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 410px; height: 362px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Distribution of sudden death in 3690 patients with a witnessed cardiac arrest. Top panel: There is a diurnal pattern with a first arrest, with a peak occurrence during the morning hours. Bottom panel: There is also a diurnal pattern of sudden death in the 597 patients with a second cardiac arrest although, for the individual patient, there was no association between the time for the first and second event.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Peckova, M, Fahrenbruch, CE, Cobb, CE, et al, Circulation 1998; 98:31.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13278=[""].join("\n");
var outline_f12_61_13278=null;
var title_f12_61_13279="JXG single face nodule 2";
var content_f12_61_13279=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59377&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Juvenile xanthogranuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 352px; height: 219px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Single nodule of juvenile xanthogranuloma on the chin of a child.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dr. Kate P&uuml;ttgen.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_61_13279=[""].join("\n");
var outline_f12_61_13279=null;
